Allergy antigens and their epitopes

Abstract

The present invention provides a novel antigen for soy allergy, a diagnostic method and kit for soy allergy, a pharmaceutical composition containing the antigen, soybeans or soybean products from which the antigen has been removed, and a tester for determining the presence or absence of soybean antigen in a target object. [Solution] A polypeptide is provided which comprises a polypeptide containing at least one amino acid sequence selected from a specific group, which specifically binds to IgE antibodies in patients with polypeptide allergies, and which has 500 or fewer amino acid residues.

Description

Technical Field

[0001] The present invention relates to a novel antigen for soybean allergy. The present invention also relates to a diagnostic kit, a diagnostic composition, and a diagnostic method for soybean allergy. The present invention also relates to a pharmaceutical composition containing the antigen, and soybean or soybean processed products from which the antigen has been removed or reduced. The present invention further relates to a tester for determining the presence or absence of soybean antigen in a subject.

[0002] The present invention also relates to a polypeptide containing an allergen epitope. The present invention also relates to a diagnostic kit, a diagnostic composition, and a diagnostic method for allergy containing the polypeptide. The present invention also relates to a pharmaceutical composition containing the polypeptide, and food raw materials or edible processed products from which the antigen containing the polypeptide has been removed or reduced, or the polypeptide has been cleaved or removed. The present invention further relates to a method for producing an edible processed product from which the antigen has been removed or reduced. The present invention further also relates to a tester for determining the presence or absence of the antigen containing the polypeptide in a subject.

Background Art

[0003] In the blood and tissues of allergic patients, IgE antibodies specific to specific antigens are produced. An allergic reaction is induced by the physiological results caused by the interaction between this IgE antibody and the specific antigen.

[0004] Conventional allergy test kits often simply grind up candidate allergen foods and materials to create antigen reagents (Patent Document 1). Thus, conventional antigen reagents do not necessarily contain a single specific antigen protein (allergen component) that causes an allergic reaction, but rather contain multiple protein components. Therefore, in conventional antigen reagents, the content of each allergen component varied. Consequently, a positive reaction in an allergy test could only be detected if the protein present in the conventional antigen reagent was an allergen component with a content exceeding the threshold for determining a positive reaction in binding to IgE antibodies. Conversely, for patients whose IgE antibodies bind to allergen components present in small amounts in allergens such as foods, a positive reaction could not be determined using conventional allergy test kits, and the diagnostic efficiency was not sufficiently high.

[0005] Furthermore, the symptoms and severity of allergic reactions do not necessarily correlate with the amount of allergen component present. Even if a patient's IgE antibodies react to trace amounts of allergen components in a potential allergen food or material, allergic symptoms may appear or be related to the severity of the reaction.

[0006] Attempts are underway to improve diagnostic efficiency by examining IgE antibodies against each component that makes up the crude antigen, thereby distinguishing between sensitization directly related to diagnosis and sensitization based on cross-reactivity with pan-allergens, etc. Regarding soy allergens, eight are currently registered with the World Health Organization / International Union for Immunology (WHO / IUIS).

[0007] However, in order to improve the reliability of allergy tests, it is necessary to comprehensively identify allergen components in candidate foods and materials, but the patient detection rate by measuring the above allergen components is still insufficient. Identifying novel soy allergens is extremely important not only for improving the accuracy of diagnostic agents but also as a target for low-allergen foods and therapeutic drugs.

[0008] On the other hand, regarding the separation and purification of proteins, various methods have been investigated to separate and purify proteins and nucleic acids from cell extracts and other sources. Dialysis using salt concentration and centrifugation are examples of such methods.

[0009] Furthermore, numerous purification methods utilizing the differences in charge and molecular weight of protein and nucleic acid residues have been investigated. Examples of purification methods utilizing charge include column chromatography using ion exchange resins and isoelectric focusing. Examples of purification methods utilizing differences in molecular weight include centrifugation, column chromatography using molecular weight sieves, and SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis).

[0010] In recent years, two-dimensional electrophoresis, which involves isoelectric focusing in the first dimension and SDS-PAGE in the second dimension, has been used as a method for separating and purifying diverse proteins from small sample sizes. The applicants have developed two-dimensional electrophoresis methods with high separation capabilities (Patent Documents 2-5).

[0011] Allergen-specific IgE antibodies recognize and bind to epitopes, which are specific amino acid sequences within allergen components. However, while there are a few examples of allergen components being analyzed down to the epitope level (Non-Patent Literature 1), such cases are extremely rare. Furthermore, there are currently no allergy diagnostic kits on the market that utilize polypeptides containing epitopes. [Prior art documents] [Patent Documents]

[0012] [Patent Document 1] Japanese Patent Publication No. 2002-286716 [Patent Document 2] Japanese Patent Publication No. 2011-33544 [Patent Document 3] Japanese Patent Publication No. 2011-33546 [Patent Document 4] Japanese Patent Publication No. 2011-33547 [Patent Document 5] Japanese Patent Publication No. 2011-33548 [Non-patent literature]

[0013] [Non-Patent Document 1] Matsuo, H., et al., J. Biol. Chem., (2004), Vol.279, No.13, pp.12135-12140 [Non-Patent Document 2] Zhao, L., et al., PLoS One. 2017 Aug 11; 12(8):e0182935. doi: 10.1371 / journal.pone.0182935. eCollection 2017. [Non-Patent Document 3] Cong, Y., et al., J Dairy Sci. 2013; 96(11):6870-6. doi: 10. 3168 / jds.2013-6880. Epub 2013 Sep 12. [Non-Patent Document 4] Beezhold, DH, et al., J Allergy Clin Immunol. 2001 Jun; 107(6):1069-76. [Overview of the Initiative] [Problems that the invention aims to solve]

[0014] This invention provides a novel antigen for soy allergy. This invention also provides a diagnostic method and a diagnostic kit for soy allergy. This invention also provides a pharmaceutical composition containing the antigen, and soy or soy products from which the antigen has been removed or reduced. Furthermore, this invention provides a tester for determining the presence or absence of soy antigen in a subject.

[0015] The present invention also provides a polypeptide containing an allergen epitope. The present invention also provides a diagnostic kit for allergy, a diagnostic composition, and a diagnostic method. The present invention also provides a pharmaceutical composition containing the polypeptide, and a food raw material or a processed food product in which the antigen containing the polypeptide is removed, reduced, or the polypeptide is cleaved or removed. The present invention further relates to a method for producing a processed food product in which the antigen is removed or reduced. The present invention also further provides a tester for determining the presence or absence of an antigen containing the polypeptide in a subject.

Means for Solving the Problems

[0016] The present inventors conducted intensive research on identifying the causative antigen of allergy in order to solve the above problems. As a result, they succeeded in identifying a novel antigen to which IgE antibodies in the sera of patients with allergies specifically bind. Based on this finding, the present invention was completed.

[0017] That is, in one aspect, the present invention may be as follows.

[0018] [1] A diagnostic kit for soybean allergy, comprising at least one of the following proteins (1α) to (55α): (1α) (1αA1) endoplasmin homolog isoform X2 or a variant thereof, and any of the following proteins (1αA1-a) to (1αA1-e): (1αA1-a) A protein containing an amino acid sequence in which one or several amino acids are deleted, substituted, inserted or added in SEQ ID NO: 70; (1αA1-b) A protein containing an amino acid sequence having 70% or more identity with the amino acid sequence shown in SEQ ID NO: 70; (1αA1-c) A protein containing an amino acid sequence encoded by a nucleotide sequence in which one or several nucleotides are deleted, substituted, inserted or added in SEQ ID NO: 69; (1αA1-d) A protein containing an amino acid sequence encoded by a nucleotide sequence having 70% or more identity with the nucleotide sequence shown in SEQ ID NO: 69; or A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 69; A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 71 to 87; (1αA2) endoplasmin homolog isoform X2 or a variant thereof, which is any one of the following proteins (1αA2-a) to (1αA2-e): (1αA2-a) A protein comprising an amino acid sequence in which one or several amino acids are deleted, substituted, inserted or added at SEQ ID NO: 89; (1αA2-b) A protein comprising an amino acid sequence having 70% or more identity with the amino acid sequence shown in SEQ ID NO: 89; (1αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides are deleted, substituted, inserted or added at SEQ ID NO: 88; (1αA2-d) A protein comprising an amino acid sequence encoded by a base sequence having 70% or more identity with the base sequence shown in SEQ ID NO: 88; or (1αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 88; or (1αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 90 to 104; (2α)(2αA1) heat shock cognate protein 80 or a variant thereof, which is any one of the following proteins (2αA1-a) to (2αA1-e): (2αA1-a) A protein comprising an amino acid sequence in which one or several amino acids are deleted, substituted, inserted or added at SEQ ID NO: 106; (2αA1-b) A protein comprising an amino acid sequence having 70% or more identity with the amino acid sequence shown in SEQ ID NO: 106; (2αA1-c) A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 105; (2αA1-d) A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in Sequence ID No. 105; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (2αA1-e)SEQ ID NO: 105; (2αB1) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 107-120; (2αA2)heat shock protein 90-1 or its variant, which is any of the following proteins (2αA2-a) to (2αA2-e): (2αA2-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 122; (2αA2-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 122; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (2αA2-c)Sequence ID 121; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (2αA2-d)Sequence No. 121; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (2αA2-e)Sequence ID 121; or (2αB2) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 123-137; (2αA3)hypothetical protein GLYMA_02G302500 or its variant, which is any of the following proteins (2αA3-a) to (2αA3-e): (2αA3-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 139; (2αA3-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 139; (2αA3-c) A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 138; (2αA3-d) A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in Sequence ID No. 138; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (2αA3-e)Sequence ID 138; or (2αB3) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 140-153; (4α)(4αA)embryo-specific urease isoform X1 or its variant, comprising any of the following proteins (4αA-a) to (4αA-e): (4αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 155; (4αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in SEQ ID NO: 155; (4αA-c) A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 154; (4αA-d) A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in Sequence ID No. 154; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (4αA-e)SEQ ID NO: 154; or (4αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 156 and 157; (5α)(5αA)alpha-1,4 glucan phosphorylase L isozyme, chloroplastic / amyloplastic or its variants, which are any of the following proteins (5αA-a) to (5αA-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (5αA-a)Sequence ID 159; (5αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 159; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (5αA-c)Sequence ID 158; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (5αA-d)Sequence No. 158; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (5αA-e)SEQ ID NO: 158; or (5αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 160 and 161; (6α)(6αA1)aconitate hydratase 1 or its variant, comprising any of the following proteins (6αA1-a) to (6αA1-e): (6αA1-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 163; (6αA1-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 163; (6αA1-c) A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 162; (6αA1-d) A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in Sequence ID No. 162; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (6αA1-e)SEQ ID NO: 162; (6αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 164-167; or (6αA2)aconitate hydratase 1 or its variants, comprising any of the following proteins (6αA2-a) to (6αA2-e): (6αA2-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 169; (6αA2-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 169; (6αA2-c) A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 168; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (6αA2-d)Sequence No. 168; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (6αA2-e)Sequence ID 168; or (6αB2) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 170-172; (7α)(7αA)methionine synthase or its variant, which is any of the following proteins (7αA-a) to (7αA-e): (7αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 174; (7αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 174; (7αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 173; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (7αA-d)Sequence No. 173; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (7αA-e)SEQ ID NO: 173; or (7αB) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 175-187; (8α)(8αA)transketolase, chloroplastic, or a variant thereof, comprising any of the following proteins (8αA-a) to (8αA-e): (8αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 189; (8αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 189; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (8αA-c)Sequence ID 188; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (8αA-d)Sequence No. 188; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (8αA-e)Sequence ID 188; or (8αB) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 190-199; (9α)(9αA)lysine-tRNA ligase, cytoplasmic-like isoform X2 or its variant, comprising any of the following proteins (9αA-a) to (9αA-e): (9αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 201; (9αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 201; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (9αA-c)Sequence ID 200; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (9αA-d)Sequence No. 200; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (9αA-e)Sequence ID 200; or (9αB) A protein containing the amino acid sequence shown in Sequence ID No. 202; (10α)(10αA1)chaperonin CPN60-2, mitochondrial, or its variant, which is any of the following proteins (10αA1-a) to (10αA1-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (10αA1-a)Sequence No. 204; (10αA1-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 204; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (10αA1-c)Sequence ID 203; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (10αA1-d)Sequence No. 203; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (10αA1-e)SEQ ID NO: 203; (10αB1) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 205-218; (10αA2)chaperonin CPN60-2, mitochondrial-like isoform X1 or its variant, which is any of the following proteins (10αA2-a) to (10αA2-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (10αA2-a)Sequence No. 220; (10αA2-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 220; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (10αA2-c)SEQ ID NO: 219; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (10αA2-d)SEQ ID NO. 219; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (10αA2-e)SEQ ID NO: 219; or (10αB2) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 221-231; (11α)(11αA)polyadenylate-binding protein 8 isoform X3 or its variant, which is any of the following proteins (11αA-a) to (11αA-e): (11αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 233; (11αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 233; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (11αA-c)Sequence ID 232; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (11αA-d)Sequence No. 232; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (11αA-e)SEQ ID NO: 232; or (11αB) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 234-237; (12α)(12αA)pyrophosphate-fructose 6-phosphate 1-phosphotransferase subunit alpha-like or a variant thereof, comprising any of the following proteins (12αA-a) to (12αA-e): (12αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 239; (12αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 239; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (12αA-c)Sequence ID 238; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (12αA-d)Sequence No. 238; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (12αA-e)SEQ ID NO: 238; or (12αB) A protein containing the amino acid sequence shown in Sequence ID No. 240; (13α)(13αA1)protein disulfide isomerase-like protein precursor or mutant thereof, which is any of the following proteins (13αA1-a) to (13αA1-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (13αA1-a)Sequence No. 242; (13αA1-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 242; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (13αA1-c)SEQ ID NO: 241; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (13αA1-d)Sequence No. 241; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (13αA1-e)SEQ ID NO: 241; (13αB1) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 243-252; (13αA2)protein disulfide-isomerase or a variant thereof, which is any of the following proteins (13αA2-a) to (13αA2-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (13αA2-a)Sequence No. 254; (13αA2-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 254; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (13αA2-c)SEQ ID NO: 253; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (13αA2-d)Sequence No. 253; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (13αA2-e)SEQ ID NO: 253; or (13αB2) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 255-278; (14α)(14αA1)V-type proton ATPase subunit B 2 or its variant, which is any of the following proteins (14αA1-a) to (14αA1-e): (14αA1-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 280; (14αA1-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 280; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (14αA1-c)Sequence ID 279; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (14αA1-d)Sequence No. 279; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (14αA1-e)SEQ ID NO: 279; (14αB1) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 281-284; (14αA2)V-type proton ATPase subunit B 2 or its variant, which is any of the following proteins (14αA2-a) to (14αA2-e): (14αA2-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 286; (14αA2-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 286; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (14αA2-c)Sequence No. 285; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (14αA2-d)Sequence No. 285; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (14αA2-e)SEQ ID NO: 285; or (14αB2) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 287-289; (15,16α)(15,16αA1)UTP-glucose-1-phosphate uridylyltransferase or a variant thereof, which is any of the following proteins (15,16αA1-a) to (15,16αA1-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (15,16αA1-a)Sequence ID 291; (15,16αA1-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 291; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (15,16αA1-c)SEQ ID NO: 290; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (15,16αA1-d)Sequence No. 290; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (15,16αA1-e)SEQ ID NO: 290; (15,16αB1) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 292-304; (15,16αA2)hypothetical protein GLYMA_02G241100 or its variant, which is any of the following proteins (15,16αA2-a) to (15,16αA2-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (15,16αA2-a)Sequence No. 306; (15,16αA2-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in SEQ ID NO: 306; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (15,16αA2-c)SEQ ID NO: 305; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (15,16αA2-d)Sequence No. 305; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (15,16αA2-e)SEQ ID NO: 305; or (15,16αB2) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 307-318; (17α)(17αA1)guanosine nucleotide diphosphate dissociation inhibitor 2 or a variant thereof, which is any of the following proteins (17αA1-a) to (17αA1-e): (17αA1-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 320; (17αA1-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 320; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (17αA1-c)Sequence ID 319; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (17αA1-d)Sequence No. 319; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (17αA1-e)SEQ ID NO: 319; (17αB1) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 321-325; (17αA2)rab GDP dissociation inhibitor alpha-like or its variant, which is any of the following proteins (17αA2-a) to (17αA2-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (17αA2-a)Sequence No. 327; (17αA2-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in SEQ ID NO: 327; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (17αA2-c)Sequence ID 326; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (17αA2-d)Sequence No. 326; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (17αA2-e)SEQ ID NO: 326; or (17αB2) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 328-332; (18α)(18αA)hypothetical protein GLYMA_10G028300 or its variants, which are any of the following proteins (18αA-a) to (18αA-e): (18αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 334; (18αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in SEQ ID NO: 334; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (18αA-c)Sequence ID 333; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (18αA-d)Sequence No. 333; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (18αA-e)SEQ ID NO: 333; or (18αB) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 335-339; (19α)(19αA)sucrose binding protein homolog S-64 or its variant, which is any of the following proteins (19αA-a) to (19αA-e): (19αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 341; (19αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in SEQ ID NO: 341; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (19αA-c)Sequence ID 340; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (19αA-d)SEQ ID NO: 340; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (19αA-e)Sequence ID 340; or (19αB) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 342-346; (25α)(25αA1)succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial, or a variant thereof, comprising any of the following proteins (25αA1-a) to (25αA1-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (25αA1-a)Sequence ID 348; (25αA1-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 348; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (25αA1-c)Sequence ID 347; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (25αA1-d)Sequence No. 347; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (25αA1-e)SEQ ID NO: 347; (25αB1) A protein containing at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 349-356; (25αA2)succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial, or a variant thereof, comprising any of the following proteins (25αA2-a) to (25αA2-e): (25αA2-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 358; (25αA2-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 358; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (25αA2-c)Sequence ID 357; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (25αA2-d)Sequence No. 357; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (25αA2-e)SEQ ID NO: 357; or (25αB2) A protein containing at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 359-365; (26α)(26αA1)phosphoglycerate kinase, cytosolic, or a variant thereof, comprising any of the following proteins (26αA1-a) to (26αA1-e): (26αA1-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 367; (26αA1-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 367; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (26αA1-c)Sequence ID 366; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (26αA1-d)Sequence No. 366; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (26αA1-e)SEQ ID NO: 366; (26αB1) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 368-382; (26αA2)phosphoglycerate kinase, cytosolic, or a variant thereof, comprising any of the following proteins (26αA2-a) to (26αA2-e): (26αA2-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 384; (26αA2-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in SEQ ID NO: 384; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (26αA2-c)Sequence ID 383; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (26αA2-d)Sequence No. 383; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (26αA2-e)SEQ ID NO: 383; (26αB2) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 385-392; (26αA3)phosphoglycerate kinase, cytosolic, or a variant thereof, comprising any of the following proteins (26αA3-a) to (26αA3-e): (26αA3-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 394; (26αA3-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 394; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (26αA3-c)SEQ ID NO: 393; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (26αA3-d)Sequence No. 393; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (26αA3-e)SEQ ID NO: 393; or (26αB3) A protein containing at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 395-409; (27α)(27αA1)alcohol dehydrogenase 1 or its variant, which is any of the following proteins (27αA1-a) to (27αA1-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (27αA1-a)Sequence ID 411; (27αA1-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 411; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (27αA1-c)SEQ ID NO: 410; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (27αA1-d)Sequence No. 410; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (27αA1-e)SEQ ID NO: 410; (27αB1) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 412-416; (27αA2)alcohol dehydrogenase 1 or its variant, which is any of the following proteins (27αA2-a) to (27αA2-e): (27αA2-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 418; (27αA2-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 418; Proteins containing an amino acid sequence encoded by a nucleotide sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (27αA2-c)Sequence ID 417; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (27αA2-d)Sequence No. 417; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (27αA2-e)SEQ ID NO: 417; (27αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 419 and 420; (27αA3)alcohol dehydrogenase 1-like or its mutant, comprising any of the following proteins (27αA3-a) to (27αA3-e): (27αA3-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 422; (27αA3-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 422; Proteins containing an amino acid sequence encoded by a nucleotide sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (27αA3-c)SEQ ID NO: 421; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (27αA3-d)Sequence No. 421; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (27αA3-e)SEQ ID NO: 421; or (27αB3) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 423-427; (28α)(28αA)35 kDa seed maturation protein isoform X1 or its mutant, which is any of the following proteins (28αA-a) to (28αA-e): (28αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 429; (28αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 429; (28αA-c) A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 428; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (28αA-d)Sequence No. 428; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (28αA-e)Sequence ID 428; or (28αB) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 430-433; (29-33α)(29-33αA1)glyceraldehyde-3-phosphate dehydrogenase isoform X1 or a variant thereof, comprising any of the following proteins (29-33αA1-a) to (29-33αA1-e): (29-33αA1-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 435; (29-33αA1-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in SEQ ID NO: 435; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (29-33αA1-c)Sequence ID 434; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (29-33αA1-d)Sequence No. 434; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (29-33αA1-e)SEQ ID NO: 434; (29-33αB1) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 436-439; (29-33αA2)glyceraldehyde-3-phosphate dehydrogenase, cytosolic, or a variant thereof, comprising any of the following proteins (29-33αA2-a) to (29-33αA2-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (29-33αA2-a)Sequence No. 441; (29-33αA2-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in SEQ ID NO: 441; (29-33αA2-c) A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 440; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (29-33αA2-d)Sequence No. 440; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (29-33αA2-e)SEQ ID NO: 440; (29-33αB2) A protein containing at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 442-445; (29-33αA3)uncharacterized protein LOC100782924 or its variants, which are any of the following proteins (29-33αA3-a) to (29-33αA3-e): (29-33αA3-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 447; (29-33αA3-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in SEQ ID NO: 447; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (29-33αA3-c)SEQ ID NO: 446; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (29-33αA3-d)SEQ ID NO: 446; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (29-33αA3-e)SEQ ID NO: 446; or (29-33αB3) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 448-451; (34α)(34αA1)bifunctional UDP-glucose 4-epimerase and UDP-xylose 4-epimerase 1-like or a variant thereof, comprising any of the following proteins (34αA1-a) to (34αA1-e): (34αA1-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 453; (34αA1-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 453; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (34αA1-c)Sequence ID 452; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (34αA1-d)Sequence No. 452; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (34αA1-e)SEQ ID NO: 452; (34αB1) A protein containing the amino acid sequence shown in SEQ ID NO: 454; (34αA2)uncharacterized protein LOC100803483 or its variant, which is any of the following proteins (34αA2-a) to (34αA2-e): (34αA2-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 456; (34αA2-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in SEQ ID NO: 456; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (34αA2-c)SEQ ID NO: 455; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (34αA2-d)Sequence No. 455; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (34αA2-e)SEQ ID NO: 455; or (34αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 457 and 458; (35α)(35αA1)elongation factor 1-alpha or its variant, which is any of the following proteins (35αA1-a) to (35αA1-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (35αA1-a)Sequence ID 460; (35αA1-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in SEQ ID NO: 460; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (35αA1-c)Sequence ID 459; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (35αA1-d)Sequence No. 459; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (35αA1-e)SEQ ID NO: 459; (35αB1) A protein containing at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 461-466; (35αA2)elongation factor 1-alpha or its variant, which is any of the following proteins (35αA2-a) to (35αA2-e): (35αA2-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 468; (35αA2-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in SEQ ID NO: 468; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (35αA2-c)Sequence ID 467; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (35αA2-d)Sequence No. 467; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (35αA2-e)SEQ ID NO: 467; (35αB2) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 469-471; (35αA3)elongation factor-1A isoform X1 or its mutant, comprising any of the following proteins (35αA3-a) to (35αA3-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (35αA3-a)Sequence ID 473; (35αA3-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 473; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (35αA3-c)SEQ ID NO: 472; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (35αA3-d)Sequence No. 472; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (35αA3-e)SEQ ID NO: 472; or (35αB3) A protein containing at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 474-477; (36,37α)(36,37αA1) seed maturation protein PM34 or its variant, which is any of the following proteins (36,37αA1-a) to (36,37αA1-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (36,37αA1-a)Sequence ID 479; (36,37αA1-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 479; Proteins containing amino acid sequences encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (36,37αA1-c)Sequence ID 478; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (36,37αA1-d)Sequence No. 478; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (36,37αA1-e)SEQ ID NO: 478; (36,37αB1) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 480-483; (36,37αA2)uncharacterized protein LOC100809384 or its variant, which is any of the following proteins (36,37αA2-a) to (36,37αA2-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (36,37αA2-a)Sequence ID 485; (36,37αA2-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 485; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (36,37αA2-c)Sequence ID 484; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (36,37αA2-d)Sequence No. 484; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (36,37αA2-e)SEQ ID NO: 484; (36,37αB2) A protein containing at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 486 and 487; (36,37αA3)hypothetical protein GLYMA_10G155300 or its variant, which is any of the following proteins (36,37αA3-a) to (36,37αA3-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (36,37αA3-a)Sequence ID 489; (36,37αA3-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 489; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (36,37αA3-c)Sequence ID 488; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (36,37αA3-d)Sequence No. 488; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (36,37αA3-e)SEQ ID NO: 488; or (36,37αB3) A protein containing at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 490-493; (38α)(38αA)seed biotin-containing protein SBP65-like isoform X1 or its variant, which is any of the following proteins (38αA-a) to (38αA-e): (38αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 495; (38αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in SEQ ID NO: 495; (38αA-c) A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 494; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (38αA-d)Sequence No. 494; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (38αA-e)SEQ ID NO: 494; or (38αB) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 496-513; (39α)(39αA)ATP synthase subunit O, mitochondrial-like, or a variant thereof, comprising any of the following proteins (39αA-a) to (39αA-e): (39αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 515; (39αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 515; (39αA-c) A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 514; (39αA-d) A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in Sequence ID No. 514; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (39αA-e)SEQ ID NO: 514; or (39αB) A protein containing the amino acid sequence shown in SEQ ID NO: 516; (40,56α)(40,56αA)P24 oleosin isoform A or its variant, which is any of the following proteins (40,56αA-a) to (40,56αA-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (40,56αA-a)Sequence ID 518; (40,56αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in SEQ ID NO: 518; Proteins containing amino acid sequences encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (40,56αA-c)SEQ ID NO: 517; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (40,56αA-d)Sequence No. 517; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (40,56αA-e)SEQ ID NO: 517; or (40,56αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 519 and 520; (41α)(41αA)uncharacterized protein At3g49720-like isoform X2 or its variant, which is any of the following proteins (41αA-a) to (41αA-e): (41αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 522; (41αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 522; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (41αA-c)Sequence ID 521; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (41αA-d)Sequence No. 521; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (41αA-e)SEQ ID NO: 521; or (41αB) A protein containing the amino acid sequence shown in Sequence ID No. 523; (42,43α)(42,43αA1)superoxide dismutase [Mn], mitochondrial or its mutant, comprising any of the following proteins (42,43αA1-a) to (42,43αA1-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (42,43αA1-a)Sequence ID 525; (42,43αA1-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 525; Proteins containing an amino acid sequence encoded by a nucleotide sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (42,43αA1-c)Sequence ID 524; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (42,43αA1-d)Sequence No. 524; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (42,43αA1-e)SEQ ID NO: 524; (42,43αB1) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 526-531; (42,43αA2)hypothetical protein GLYMA_04G221300 or its variant, which is any of the following proteins (42,43αA2-a) to (42,43αA2-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (42,43αA2-a)Sequence ID 533; (42,43αA2-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 533; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (42,43αA2-c)Sequence ID 532; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (42,43αA2-d)Sequence No. 532; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (42,43αA2-e)SEQ ID NO: 532; or (42,43αB2) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 534-539; (45α)(45αA1)uncharacterized protein LOC100499771 or its variant, which is any of the following proteins (45αA1-a) to (45αA1-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (45αA1-a)Sequence ID 541; (45αA1-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 541; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (45αA1-c)SEQ ID NO: 540; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (45αA1-d)SEQ ID NO: 540; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (45αA1-e)SEQ ID NO: 540; (45αB1) A protein containing at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 542-545; (45αA2)hypothetical protein GLYMA_09G192800 or its variant, which is any of the following proteins (45αA2-a) to (45αA2-e): (45αA2-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 547; (45αA2-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 547; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (45αA2-c)SEQ ID NO: 546; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (45αA2-d)Sequence No. 546; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (45αA2-e)SEQ ID NO: 546; or (45αB2) A protein containing at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 548-551; (46α)(46αA)seed maturation protein PM22 or its variants, which are any of the following proteins (46αA-a) to (46αA-e): (46αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 553; (46αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in SEQ ID NO: 553; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (46αA-c)Sequence ID 552; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (46αA-d)Sequence No. 552; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (46αA-e)SEQ ID NO: 552; or (46αB) A protein containing the amino acid sequence shown in SEQ ID NO: 554; (47α)(47αA1)eukaryotic translation initiation factor 5A-2 or its variant, which is any of the following proteins (47αA1-a) to (47αA1-e): (47αA1-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 556; (47αA1-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in SEQ ID NO: 556; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (47αA1-c)SEQ ID NO: 555; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (47αA1-d)Sequence No. 555; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (47αA1-e)SEQ ID NO: 555; (47αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 557 and 558; (47αA2)uncharacterized protein LOC100305510 or its variants, which are any of the following proteins (47αA2-a) to (47αA2-e): (47αA2-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 560; (47αA2-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in SEQ ID NO: 560; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (47αA2-c)SEQ ID NO: 559; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (47αA2-d)Sequence No. 559; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (47αA2-e)SEQ ID NO: 559; or (47αB2) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 561-563; (48α)(48αA)uncharacterized protein LOC100306570 or its variant, which is any of the following proteins (48αA-a) to (48αA-e): (48αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 565; (48αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in SEQ ID NO: 565; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (48αA-c)Sequence ID 564; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (48αA-d)Sequence No. 564; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (48αA-e)SEQ ID NO: 564; or (48αB) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 566-570; (50α)(50αA)uncharacterized protein LOC100813859 or its variant, which is any of the following proteins (50αA-a) to (50αA-e): (50αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 572; (50αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 572; Proteins containing amino acid sequences encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (50αA-c)Sequence ID 571; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (50αA-d)Sequence No. 571; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (50αA-e)SEQ ID NO: 571; or (50αB) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 573-576; (51α)(51αA)14-3-3-like protein or a variant thereof, which is any of the following proteins (51αA-a) to (51αA-e): (51αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 578; (51αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in SEQ ID NO: 578; (51αA-c) A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 577; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (51αA-d)Sequence No. 577; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (51αA-e)Sequence ID 577; or (51αB) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 579-582; (52α)(52αA)probable fructokinase-4 or its variant, comprising any of the following proteins (52αA-a) to (52αA-e): (52αA-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 584; (52αA-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 584; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (52αA-c)Sequence ID 583; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (52αA-d)Sequence No. 583; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (52αA-e)Sequence ID 583; or (52αB) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 585-588; (53α)(53αA1)triosephosphate isomerase isoform X1 or a variant thereof, which is any of the following proteins (53αA1-a) to (53αA1-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (53αA1-a)Sequence ID 590; (53αA1-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 590; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (53αA1-c)Sequence ID 589; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (53αA1-d)Sequence No. 589; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (53αA1-e)SEQ ID NO: 589; (53αB1) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 591-597; (53αA2)triosephosphate isomerase, cytosolic, or a variant thereof, comprising any of the following proteins (53αA2-a) to (53αA2-e): (53αA2-a) Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 599; (53αA2-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 599; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (53αA2-c)Sequence ID 598; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (53αA2-d)Sequence No. 598; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (53αA2-e)SEQ ID NO: 598; or (53αB2) A protein containing at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 600-604; (54α)(54αA1)superoxide dismutase [Fe], chloroplastic isoform X1 or its variant, which is any of the following proteins (54αA1-a) to (54αA1-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (54αA1-a)Sequence ID 606; (54αA1-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in SEQ ID NO. 606; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (53αA1-c)SEQ ID NO: 605; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (54αA1-d)SEQ ID NO. 605; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (54αA1-e)SEQ ID NO: 605; (54αB1) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 607-611; (54αA2)iron-superoxide dismutase or a variant thereof, comprising any of the following proteins (54αA2-a) to (54αA2-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (54αA2-a)Sequence ID 613; (54αA2-b) Proteins containing amino acid sequences that are 70% or more identical to the amino acid sequence shown in Sequence ID No. 613; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (54αA2-c)SEQ ID NO: 612; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (54αA2-d)Sequence No. 612; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (54αA2-e)SEQ ID NO: 612; or (54αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 614-616; or (55α)(55αA1) 51 kDa seed maturation protein precursor or its mutant, which is any of the following proteins (55αA1-a) to (55αA1-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (55αA1-a)Sequence ID 618; (55αA1-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 618; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (55αA1-c)SEQ ID NO: 617; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (55αA1-d)SEQ ID NO. 617; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (55αA1-e)SEQ ID NO: 617; (55αB1) A protein containing at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 619-635; (55αA2)Lea protein precursor or its mutant, which is any of the following proteins (55αA2-a) to (55αA2-e): Proteins containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in (55αA2-a)Sequence ID 637; (55αA2-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in Sequence ID No. 637; Proteins containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (55αA2-c)SEQ ID NO: 636; A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (55αA2-d)SEQ ID NO. 636; or A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (55αA2-e)SEQ ID NO: 636; or (55αB2) A protein containing at least one amino acid sequence selected from the group consisting of sequence numbers 638-649; The diagnostic kit comprising as an antigen.

[0019] [2] A diagnostic composition for soy allergy, comprising at least one of the proteins specified as (1α) to (55α) in [1] above as an antigen.

[0020] [3] A method for providing indicators for diagnosing a target soy allergy, comprising the following steps: (i) The sample obtained from the subject is brought into contact with the antigen, where the sample is a solution containing Ig antibodies; (ii) Detect the binding of IgE antibodies to the antigen in the sample obtained from the subject; (iii) If binding of the target IgE antibody to the antigen is detected, it provides an indicator that the subject has a soy allergy; The method comprising, wherein the antigen is at least one of the proteins identified as (1α) to (55α) in [1] above.

[0021] [4] A pharmaceutical composition comprising at least one of the proteins specified as (1α) to (55α) in [1] above.

[0022] [5] The pharmaceutical composition described in [4] above for the treatment of soy allergy.

[0023] [6] Soybeans or soybean products characterized in that an antigen is removed or reduced, wherein the antigen is at least one of the proteins specified as (1α) to (55α) in [1] above.

[0024] [7] A method for producing a soy product in which an antigen has been removed or reduced, the method comprising the step of confirming that the antigen has been removed or reduced during the production process of the product, wherein the antigen is at least one of the proteins identified as (1α) to (55α) in [1] above.

[0025] [8] A tester for determining the presence or absence of soybean antigen in a target object, characterized by comprising an antibody that binds to at least one of the proteins identified as (1α) to (55α) in [1] above.

[0026] [9] An antigen derived from soybeans, which is at least one of the proteins identified as (1α) to (55α) in [1] above, and which causes an allergy to soybeans.

[0027] The inventors also succeeded in identifying an epitope for the novel antigen.

[0028] As described above, allergic reactions are triggered by the interaction between IgE antibodies of allergy sufferers and specific antigens. Here, the IgE antibodies recognize and bind to epitopes, which are specific amino acid sequences in allergen components. Since epitopes have relatively short amino acid sequences, if the same amino acid sequence exists in different allergen components, the IgE antibodies can bind to multiple allergen components. When IgE antibodies of allergy sufferers bind to both allergen components as a result of the existence of common epitopes in different allergen components, the allergens exhibit cross-reactivity (also referred to as cross-antigenicity). Therefore, the epitopes identified in this application enable the diagnosis and treatment of allergies, including cross-reactivity, and the detection of multiple allergen components containing the epitopes.

[0029] Based on these findings, the present invention was completed. That is, in another embodiment, the present invention may be as follows:

[0030]

[10] A polypeptide that specifically binds to IgE antibodies in allergy patients, the following: (1β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 650-660; (2β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 661-692; (4β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of sequence numbers 717-731; (5β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of sequence numbers 732-738; (6β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 739 and 740; (7β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 741-744; (9β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 745-749; (11β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 751-754; (12β) Polypeptide containing the amino acid sequence of SEQ ID NO: 755; (13β) Polypeptide containing the amino acid sequence of SEQ ID NOs. 756-758; (14β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 759-764; (15β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 765 and 766; (17β) Polypeptide containing the amino acid sequence of sequence number 767; (18β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 750, 768-775; (19β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of sequence numbers 776-787; (25β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 814 and 815; (26β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 816-819; (27β) Polypeptide containing the amino acid sequence of SEQ ID NO: 820; (28β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of sequence numbers 821-835; (29β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of sequence numbers 836-839; (34β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 840-846; (35β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 847-856; (36β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 857-861; (38β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of sequence numbers 862-892; (39β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of sequence numbers 893-895; (40β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 896-902; (41β) Polypeptide containing the amino acid sequence of SEQ ID NO: 903; (42β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 904-906; (45β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 910-912; (46β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 913-915; (47β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 916-918; (48β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of sequence numbers 919-922; (50β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 924-927; (51β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of sequence numbers 928-930; (52β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of sequence numbers 931-938; (53β) Polypeptide containing the amino acid sequence of SEQ ID NO: 939; (54β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 940-943; (55β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 944-952; The polypeptide, which is one of the following.

[0031]

[11] A polypeptide that specifically binds to IgE antibodies in allergy patients, the following: (3β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of sequence numbers 693-716; (20β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of sequence numbers 788-792; (21β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of sequence numbers 793-802; (22β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 803 to 808; (23β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of sequence numbers 809-812; (24β) Polypeptide containing the amino acid sequence of SEQ ID NO: 813; (44β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 907-909; (49β) Polypeptide containing the amino acid sequence of sequence number 923; (57β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 953-955; (58β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 956-960; (59β) A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 961 and 962; (60β) Polypeptide containing the amino acid sequence of SEQ ID NO: 963; The polypeptide, which is one of the following.

[0032]

[12] The polypeptide described in

[10] or

[11] above, wherein the number of amino acid residues is 500 or less.

[0033]

[13] An allergy diagnostic kit comprising at least one of the polypeptides described in any one of the above items

[10] to

[12] .

[0034]

[14] A diagnostic composition for allergies, comprising at least one of the polypeptides described in any one of the above

[10] to

[12] as an antigen.

[0035]

[15] A method for providing an indicator for diagnosing a target allergy, comprising the following steps: (i) The sample obtained from the subject is brought into contact with the antigen, where the sample is a solution containing Ig antibodies; (ii) Detect the binding of IgE antibodies to the antigen in the sample obtained from the subject; (iii) If binding of the target IgE antibody to the antigen is detected, it provides an indicator that the subject is allergic; The method comprising, wherein the antigen is at least one of the polypeptides described in any one of the above

[10] to

[12] .

[0036]

[16] A pharmaceutical composition comprising at least one polypeptide described in any one of the above items

[10] to

[12] .

[0037]

[17] The pharmaceutical composition described in

[16] above for the treatment of allergies.

[0038]

[18] A tester for determining the presence or absence of an antigen in a target object, characterized by comprising an antibody that binds to at least one of the polypeptides described in any one of the above items

[10] to

[12] .

[0039]

[19] A food ingredient or processed food product characterized in that an antigen is removed or reduced, or a polypeptide is cleaved or removed, wherein the antigen is at least one of the polypeptides described in any one of

[10] to

[12] above.

[0040]

[20] A method for producing an edible processed product in which an antigen has been removed or reduced, or a polypeptide has been cleaved or removed, the method comprising a step of confirming that the antigen has been removed or reduced, or that the polypeptide has been cleaved or removed, in the process of producing the processed product, wherein the antigen is at least one of the polypeptides described in any one of

[10] to

[12] above. [Effects of the Invention]

[0041] The present invention can provide a novel antigen for soy allergy. Since a novel antigen (allergen component) that causes soy allergy has been identified in the present invention, it is possible to provide a highly sensitive diagnostic method and diagnostic kit for soy allergy, a pharmaceutical composition containing the antigen, and soy or soy products from which the antigen has been removed or reduced.

[0042] Furthermore, the present invention can provide novel polypeptides containing allergen epitopes. By utilizing the polypeptides of the present invention, it is possible to provide highly sensitive diagnostic methods and diagnostic kits for allergies, pharmaceutical compositions containing the polypeptides, and food ingredients or processed foods in which antigens containing the polypeptides have been removed or reduced, or the polypeptides have been cleaved or removed, as well as methods for producing the processed foods. [Brief explanation of the drawing]

[0043] [Figure 1] Figure 1 is a photograph of a gel showing the electrophoresis pattern of proteins contained in soybeans, obtained by two-dimensional electrophoresis. The band on the left side of the photograph is the molecular weight marker band. [Figure 2] Figure 2 shows an immunoblot image of the two-dimensional electrophoresis pattern of proteins contained in soybeans, using serum from healthy subjects. [Figure 3A] Figure 3A is a photograph of an immunoblot using the serum of soy allergy patient 1α against a two-dimensional electrophoresis pattern of proteins contained in soybeans. Spots indicated by white lines or enclosed in squares represent spots where the serum of the soy allergy patient specifically reacted. The numbers (n) indicate the number of each spot, corresponding to the spot designated as "nα" in this specification. [Figure 3B] Figure 3B is a photograph of an immunoblot using the serum of soybean allergy patient 2α against a two-dimensional electrophoresis pattern of proteins contained in soybeans. Spots indicated by white lines or enclosed in squares represent spots where the serum of the soybean allergy patient specifically reacted. The numbers (n) indicate the number of each spot, corresponding to the spot designated as "nα" in this specification. [Figure 3C] Figure 3C is a photograph of an immunoblot using the serum of soybean allergy patient 3α against a two-dimensional electrophoresis pattern of proteins contained in soybeans. Spots indicated by white lines or enclosed in squares represent spots where the serum of the soybean allergy patient specifically reacted. The numbers (n) indicate the number of each spot, corresponding to the spot designated as "nα" in this specification. [Figure 3D] Figure 3D is a photograph of an immunoblot using the serum of soy allergy patient 4α against a two-dimensional electrophoresis pattern of proteins contained in soybeans. The spots indicated by the white lines are those where the serum of the soy allergy patient specifically reacted. The numbers (n) indicate the number of each spot, corresponding to the spot identified as "nα" in this specification. [Figure 3E] Figure 3E is a photograph of an immunoblot using the serum of soybean allergy patient 5α against a two-dimensional electrophoresis pattern of proteins contained in soybeans. The spots indicated by the white lines are those where the serum of the soybean allergy patient specifically reacted. The numbers (n) indicate the number of each spot, corresponding to the spot identified as "nα" in this specification. [Figure 3F] Figure 3F is a photograph of an immunoblot using the serum of soybean allergy patient 6α against a two-dimensional electrophoresis pattern of proteins contained in soybeans. Spots indicated by white lines or enclosed in squares represent spots where the serum of the soybean allergy patient specifically reacted. The numbers (n) indicate the number of each spot, corresponding to the spot designated as "nα" in this specification. [Figure 3G] Figure 3G is a photograph of an immunoblot using the serum of soybean allergy patient 7α against a two-dimensional electrophoresis pattern of proteins contained in soybeans. The spots enclosed in squares indicate spots where the serum of the soybean allergy patient specifically reacted. The numbers (n) indicate the number of each spot, corresponding to the spot identified as "nα" in this specification. [Figure 3H] Figure 3H is a photograph of an immunoblot using the serum of soybean allergy patient 8α against a two-dimensional electrophoresis pattern of proteins contained in soybeans. The spots indicated by white lines or enclosed in squares are the spots where the serum of the soybean allergy patient specifically reacted. The numbers (n) indicate the number of each spot, corresponding to the spot identified as "nα" in this specification. [Figure 3I] Figure 3I is a photograph of an immunoblot using the serum of soybean allergy patient 9α against a two-dimensional electrophoresis pattern of proteins contained in soybeans. Spots indicated by white lines or enclosed in squares represent spots where the serum of the soybean allergy patient specifically reacted. The numbers (n) indicate the number of each spot, corresponding to the spot designated as "nα" in this specification. [Figure 4] Figure 4 shows an example of the results obtained when determining the peptide with the minimum number of amino acids that functions as an epitope using the overlapping method. [Figure 5] Figure 5 shows an example of the results obtained when examining the location of an epitope identified using the alanine scan method, focusing on the location important for antigenic expression. [Figure 6] Figure 6 is a graph showing the results of the cross-reactivity study. [Modes for carrying out the invention]

[0044] The present invention will be described in detail below, but the present invention is not limited to these descriptions.

[0045] Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have meanings that are generally understood by those skilled in the art.

[0046] In this specification, when an amino acid sequence is shown, it shall be represented by the single-letter abbreviation of the amino acid, which is well known to those skilled in the art, with the leftmost terminology being the amino terminology and the rightmost terminology being the carboxyl terminology.

[0047] In this specification, allergy refers to a condition in which a body exhibits an adverse hypersensitivity reaction when an antigen that has been sensitized to a particular antigen is reintroduced to that antigen. In many food allergies, antigen-specific IgE antibodies are produced in the blood and tissues. These IgE antibodies bind to mast cells or basophils. When an antigen specific to these IgE antibodies reintroduces into the body of an allergic patient, the antigen combines with the IgE antibodies bound to mast cells or basophils, and these IgE antibodies cross-link on the cell surface, producing the physiological effects of IgE antibody-antigen interaction. These physiological effects include the release of histamine, serotonin, heparin, eosinophil migration factors, or various leukotrienes. These released substances trigger allergic reactions caused by the combination of IgE antibodies and specific antigens. Allergic reactions to specific antigens manifest through the above pathway.

[0048] The allergies covered by the present invention are not particularly limited, as long as they are allergies to allergens containing the epitopes used. Such allergies may include allergies to plants of the Malvaceae, Rubiaceae, Brassicaceae, Poaceae, Cucurbitaceae, Asteraceae, Lamiaceae, Juglandaceae, Rhamnaceae, Pedicularaceae, Apiaceae, Euphorbiaceae, Solanaceae, Bromeliaceae, Papayaaceae, Rosaceae, Amaranthaceae, Vitaceae, Fabaceae, Lythraceae and / or Betulaceae families. Examples of plants in the Malvaceae family include molokhia (scientific name: Corchorus olitorius) and cacao (scientific name: Theobroma cacao), examples of plants in the Rubiaceae family include robusta coffee (scientific name: Coffea canephora), examples of plants in the Brassicaceae family include bok choy (scientific name: Brassica rapa), radish (scientific name: Raphanus sativus), and rapeseed (scientific name: Brassica napus), examples of plants in the Poaceae family include sorghum (scientific name: Sorghum bicolor), maize (scientific name: Zea mays), and bread wheat (scientific name: Triticum aestivum), examples of plants in the Cucurbitaceae family include melon (scientific name: Cucumis melo), bitter melon (scientific name: Momordica charantia), and cucumber (scientific name: Cucumis Examples include sativus, sunflower (scientific name Helianthus annuus) from the Asteraceae family, asparagus (scientific name Asparagus officinalis) from the Lamiaceae family, Japanese walnut (scientific name Juglans regia) from the Juglandaceae family, jujube (scientific name Ziziphus jujuba) from the Rhamnaceae family, sesame (scientific name Sesamum indicum) from the Sesameaceae family, and carrot (scientific name Daucus carota subsp.) from the Apiaceae family.Examples include Sativus, etc., and among the plants of the Euphorbiaceae family, cassava (scientific name Manihot esculenta) is an example. Among the plants of the Solanaceae family, chili peppers (scientific name Capsicum annuum) and tomatoes (scientific name Solanum lycopersicum) are examples. Among the plants of the Bromeliaceae family, pineapples (scientific name Ananas comosus) are examples. Among the plants of the Papayaaceae family, papaya (scientific name Carica papaya) is an example. Among the plants of the Rosaceae family, apples (scientific name Malus domestica), European cherry blossoms (scientific name Prunus avium), and peaches (scientific name Prunus persica) are examples. Among the plants of the Amaranthaceae family, quinoa (scientific name Chenopodium quinoa), spinach (scientific name Spinacia oleracea), and beets (scientific name Beta vulgaris subsp. Examples of allergens include *Vulgaris*, etc., and among the plants of the Vitaceae family, examples include European grape (scientific name: *Vitis vinifera*), among the Fabaceae family, examples include pigeon pea (scientific name: *Cajanus cajan*), adzuki bean (scientific name: *Vigna angularis*), wild soybean (scientific name: *Glycine soja*), and soybean (scientific name: *Glycine max*), among the Lythraceae family, examples include pomegranate (scientific name: *Punica granatum*), and among the Betulaceae family, examples include white birch (scientific name: *Betula platyphylla*). Allergies can occur when an allergic reaction occurs upon contact with an antigen or upon ingestion of that antigen. Here, contact refers to touching an object, and in particular, in the case of the human body, it refers to adhesion to the skin, mucous membranes (eyes, lips, etc.), etc. Ingestion refers to taking something into the body, including by inhalation or oral ingestion. Generally, an allergic reaction that occurs when food is ingested is specifically called a food allergy. In a preferred embodiment, the allergy may be a food allergy.

[0049] In this specification, allergy to soybeans refers to a condition in which an allergic reaction occurs in response to proteins or other substances contained in soybeans as antigens.

[0050] In this specification, an antigen is a substance that elicits an allergic reaction, and is also referred to as an allergen component. Antigens are preferably proteins.

[0051] In this specification, a protein is defined as a molecule having a structure in which natural amino acids are linked by peptide bonds. The number of amino acids contained in a protein is not particularly limited. In this specification, the term "polypeptide" also refers to a molecule having a structure in which natural amino acids are linked by peptide bonds. The number of amino acids contained in a polypeptide is not particularly limited. "Polypeptide" is a concept that includes "protein". Furthermore, a polypeptide in which approximately 2 to 50 amino acids are linked by peptide bonds is sometimes specifically called a peptide. In addition, if optical isomers of an amino acid are possible, the L-form is indicated unless otherwise specified. The notation of amino acid sequences of proteins, polypeptides, or peptides used in this specification is based on standard usage and notation commonly used in this industry, and is represented by a single letter notation of the amino acid, with the left direction being the amino-terminus direction and the right direction being the carboxy-terminus direction. In the single letter notation of an amino acid, X may be any substance having an amino group and a carboxyl group that can bond to the amino acids at both ends, and may be any of the 20 natural amino acids in particular.

[0052] Identification of antigens Using the methods described above, we identified antigens that cause soy allergies in proteins contained in soybeans. Specifically, soybean proteins were subjected to two-dimensional electrophoresis under the following conditions.

[0053] For the first dimension of electrophoresis, isoelectric focusing was performed using an IPG gel Immobiline Drystrip (pH3-10NL) manufactured by GE Healthcare Biosciences Corporation (hereinafter abbreviated as GE). The gel length was within the range of 5-10 cm, the pH range of the gel was within the range of 3-10, and the pH gradient of the gel relative to the electrophoresis direction was within the range of 0.15-0.3, with the gel length up to pH 5 being defined as a, the gel length from pH 5 to 7 being b, and the gel length above pH 7 being c. Specifically, isoelectric focusing was performed using an IPG gel Immobiline Drystrip (pH3-10NL) manufactured by GE Healthcare Biosciences Corporation (hereinafter abbreviated as GE). The electrophoresis apparatus used was an IPGphor manufactured by GE. The current limit of the electrophoresis equipment was set to 75 μA per gel, and the voltage program was as follows: (1) A constant voltage process was performed at 300 V for up to 750 Vhr (the current change range during the 30 minutes of electrophoresis before the end of this process was 5 μA), (2) the voltage was gradually increased to 1000 V over 300 Vhr, (3) the voltage was further gradually increased to 5000 V over 4500 Vhr, and (4) the first dimension of isoelectric focusing was performed at a constant voltage of 5000 V until the total Vhr reached 12000.

[0054] For the second dimension of electrophoresis, a polyacrylamide gel was used, with the gel concentration at the proximal end of the electrophoresis direction set to 3-6%, and the gel concentration at the leading end of the electrophoresis direction set to a higher concentration. Specifically, SDS-PAGE was performed using a NuPAGE 4-12% Bris-Tris Gels IPG well mini 1mm from Life Technologies. The electrophoresis apparatus used was the XCell SureLock Mini-Cell from Life Technologies. 50 mM MOPS and 50 mM electrophoresis buffers were used. Tris base, 0.1% (w / v) SDS, and 1m MEDTA were used for electrophoresis at a constant voltage of 200V for approximately 45 minutes.

[0055] As a result, we revealed that in the gel obtained by performing two-dimensional electrophoresis on soy protein under the above conditions, the following spots specifically bind to IgE antibodies of patients with soy allergies. Spot 1α: Molecular weight 70-120 kDa, pI 2.5-6.5 Spot 2α: Molecular weight 50-120 kDa, pI 2.5-6.5 Spot 4α: Molecular weight 70-120 kDa, pI 3.5-7.5 Spot 5α: Molecular weight 70-170 kDa, pI 3.5-7.5 Spot 6α: Molecular weight 70-120 kDa, pI 3.5-7.5 Spot 7α: Molecular weight 50-120 kDa, pI 3.5-7.5 Spot 8α: Molecular weight 50-120 kDa, pI 3.5-8.5 Spot 9α: Molecular weight 50-120 kDa, pI 3.5-8.5 Spot 10α: Molecular weight 30-90 kDa, pI 3.5-7.5 Spot 11α: Molecular weight 30-90 kDa, pI 3.5-8.5 Spot 12α: Molecular weight 30-90 kDa, pI 3.5-8.5 Spot 13α: Molecular weight 30-90 kDa, pI 3.5-7.5 Spot 14α: Molecular weight 30-90 kDa, pI 2.5-6.5 Spot 15α, 16α: Molecular weight 20-90 kDa, pI 3.5-7.5 Spot 17α: Molecular weight 20-90 kDa, pI 3.5-7.5 Spot 18α: Molecular weight 30-90 kDa, pI 3.5-8.5 Spot 19α: Molecular weight 30-90 kDa, pI 3.5-8.5 Spot 25α: Molecular weight 20-90 kDa, pI 3.5-7.5 Spot 26α: Molecular weight 20-90 kDa, pI 3.5-7.5 Spot 27α: Molecular weight 20-90 kDa, pI 3.5-7.5 Spot 28α: Molecular weight 10-70 kDa, pI 3.5-7.5 Spots 29α, 30α, 31α, 32α, 33α: Molecular weight 10-70 kDa, pI 3.5-8.5 Spot 34α: Molecular weight 10-70 kDa, pI 5.5-10.5 Spot 35α: Molecular weight 20-90 kDa, pI 5.5-10.5 Spot 36α, 37α: Molecular weight 10-70 kDa, pI 3.5-8.5 Spot 38α: Molecular weight 70-170 kDa, pI 5.5-10.5 Spot 39α: Molecular weight 5-60 kDa, pI 5.5-10.5 Spot 40α, 56α: Molecular weight 5-60 kDa, pI 5.5-10.5 Spot 41α: Molecular weight 5-60 kDa, pI 5.5-10.5 Spot 42α, 43α: Molecular weight 5-60 kDa, pI 5.5-10.5 Spot 45α: Molecular weight 2-50 kDa, pI 3.5-7.5 Spot 46α: Molecular weight 2-50 kDa, pI 3.5-7.5 Spot 47α: Molecular weight 5-50 kDa, pI 3.5-7.5 Spot 48α: Molecular weight 2-50 kDa, pI 3.5-8.5 Spot 50α: Molecular weight 2-50 kDa, pI 2.5-6.5 Spot 51α: Molecular weight 5-60 kDa, pI 2.5-6.5 Spot 52α: Molecular weight 10-70 kDa, pI 3.5-7.5 Spot 53α: Molecular weight 5-60 kDa, pI 3.5-8.5 Spot 54α: Molecular weight 5-60 kDa, pI 3.5-8.5 Spot 55α: Molecular weight 30-90 kDa, pI 5.5-10.5

[0056] antigen (1α) Spot 1α antigen Mass spectrometry analysis of spot 1α revealed the amino acid sequences corresponding to sequence numbers 71-104.

[0057] Furthermore, when the mass data obtained from the mass spectrometer for spot 1α was compared with the protein data from NCBI, endoplasmin homolog isoform X2 (amino acid sequence: SEQ ID NO: 70, encoding nucleotide sequence: SEQ ID NO: 69) was identified as a protein containing one of SEQ ID NOs: 71-87, and endoplasmin homolog isoform X2 (amino acid sequence: SEQ ID NO: 89, encoding nucleotide sequence: SEQ ID NO: 88) was identified as a protein containing one of SEQ ID NOs: 90-104.

[0058] Therefore, in this application, the antigen of spot 1α may be any protein selected from the group consisting of (1αA1-a) to (1αA1-e), (1αB1), (1αA2-a) to (1αA2-e), and (1αB2). (1αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 70. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (1αA1-b)Sequence ID 70. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (1αA1-c)Sequence ID 69. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (1αA1-d)Sequence ID 69, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (1αA1-e)Sequence Number 69. (1αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 71 to 87, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 71 to 87 may have one or more amino acids deleted, substituted, inserted, or added. (1αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 89. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (1αA2-b)Sequence ID 89. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (1αA2-c)Sequence ID 88. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (1αA2-d)Sequence ID 88, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (1αA2-e)Sequence Number 88. (1αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 90-104, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs: 71-87 may have one or more amino acids deleted, substituted, inserted, or added.

[0059] Proteins selected from the group consisting of (1αA1-a) to (1αA1-e), (1αB1), (1αA2-a) to (1αA2-e), and (1αB2) may appear as spots on a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 70 to 120 kDa, preferably around 80 to 110 kDa, and an isoelectric point of 2.5 to 6.5, preferably 3.0 to 6.0.

[0060] Furthermore, the epitopes of the antigens (1αA1-a) to (1αA1-e) and (1αB1) are located at amino acids 546-553 (sequence number 652), 653-661 (sequence number 655), 781-795 (sequence number 657), 252-266 (sequence number 658), 771-785 (sequence number 659), and 493-502 (sequence number 660) of sequence number 70. If the antigen of spot 1α contains a mutation in the amino acid sequence of sequence number 70, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence in sequence number 70.

[0061] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be identified as positive) and specificity (the degree to which healthy individuals are not identified as positive), the spot 1α antigen may also be one of the following variants.

[0062] Of the epitopes having the sequence of SEQ ID NO: 652, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 650 or 651. Therefore, in another preferred embodiment, if the antigen of spot 1α contains a mutation in the amino acids of SEQ ID NO: 70, then the antigen may have amino acids 546-553 in SEQ ID NO: 70 corresponding to the amino acid sequence of SEQ ID NO: 650 or 651.

[0063] Of the epitopes having the sequence of SEQ ID NO: 655, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 653 or 654. Therefore, in another preferred embodiment, if the antigen of spot 1α contains a mutation in the amino acid sequence of SEQ ID NO: 70, then the antigen may have amino acids 653-661 in SEQ ID NO: 70 being the amino acid sequence of SEQ ID NO: 653 or 654.

[0064] Of the epitopes having the sequence of SEQ ID NO: 657, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 656. Therefore, in another preferred embodiment, if the antigen of spot 1α contains a mutation in the amino acid sequence of SEQ ID NO: 70, then the antigen may have amino acids 781-795 in SEQ ID NO: 70 being the amino acid sequence of SEQ ID NO: 656.

[0065] Preferably, the antigen protein of spot 1α has activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 70 or 89 (endoplasmin homolog isoform X2), or is the cause of allergy to soy.

[0066] (2α) Spot 2α antigen Mass spectrometry analysis of spot 2α revealed the amino acid sequences corresponding to sequence numbers 107-153.

[0067] Furthermore, when the mass data obtained from the mass spectrometer for spot 2α was compared with NCBI's protein data and analyzed, the following proteins were identified: heat shock cognate protein 80 (amino acid sequence: SEQ ID NO: 106, encoding nucleotide sequence: SEQ ID NO: 105) containing one of SEQ ID NOs: 107-120; heat shock protein 90-1 (amino acid sequence: SEQ ID NO: 122, encoding nucleotide sequence: SEQ ID NO: 121) containing one of SEQ ID NOs: 123-137; and hypothetical protein GLYMA_02G302500 containing one of SEQ ID NOs: 140-153.

[0068] Therefore, in this application, the antigen of spot 1α may be any protein selected from the group consisting of (2αA1-a)~(2αA1-e), (2αB1), (2αA2-a)~(2αA2-e), (2αB2), (2αA3-a)~(2αA3-e), and (2αB3). (2αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 106. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (2αA1-b)Sequence ID 106. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (2αA1-c)Sequence ID 105. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (2αA1-d)Sequence ID 105, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (2αA1-e)Sequence ID 105. (2αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 107-120, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs: 107-120 may have one or more amino acids deleted, substituted, inserted, or added. (2αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 122. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (2αA2-b)Sequence ID 122. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (2αA2-c)Sequence ID 121. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (2αA2-d)Sequence ID 121, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (2αA2-e)Sequence ID 121. (2αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 123-137, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs: 123-137 may have one or more amino acids deleted, substituted, inserted, or added. (2αA3-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 139. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (2αA3-b)Sequence ID 139. (2αA3-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 138. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (2αA3-d)Sequence ID 138, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (2αA3-e)Sequence ID 138. (2αB3) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 140-153, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs: 140-153 may have one or more amino acids deleted, substituted, inserted, or added.

[0069] Proteins selected from the group consisting of (2αA1-a)~(2αA1-e), (2αB1), (2αA2-a)~(2αA2-e), (2αB2), (2αA3-a)~(2αA3-e), and (2αB3) may appear as spots on a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 50~120 kDa, preferably around 60~110 kDa, and an isoelectric point of 2.5~6.5, preferably 3.0~6.0.

[0070] Furthermore, the epitopes of the antigens (2αA1-a)~(2αA1-e) and (2αB1) are amino acids 42~50 (sequence number 663), 51~65 (sequence number 666), 69~73 (sequence number 669), 221~235 (sequence number 670), 351~365 (sequence number 671), 361~375 (sequence number 672), and 411~425 (sequence number 675) of sequence number 106. These are present in amino acids 551-565 (SEQ ID NO: 676), 671-685 (SEQ ID NO: 677), 681-695 (SEQ ID NO: 678), 41-55 (SEQ ID NO: 681), 451-465 (SEQ ID NO: 684), 271-285 (SEQ ID NO: 689), 51-59 (SEQ ID NO: 690), 65-72 (SEQ ID NO: 691), and 453-460 (SEQ ID NO: 692). If the antigen of spot 2α contains a mutation in the amino acid sequence of SEQ ID NO: 106, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence in SEQ ID NO: 106.

[0071] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be identified as positive) and specificity (the degree to which healthy individuals are not identified as positive), the spot 2α antigen may also be one of the following variants.

[0072] Among the epitopes having the sequence of SEQ ID NO: 663, the site indicated by an amino acid other than X at SEQ ID NO: 661 or 662 is important for binding to the IgE antibody of allergic patients. Therefore, in another preferred embodiment, when the antigen of Spot 2α contains mutations with respect to the amino acid sequence of SEQ ID NO: 106, the antigen may be such that amino acids 42 to 50 in SEQ ID NO: 106 are the amino acid sequences of SEQ ID NO: 661 or 662.

[0073] Among the epitopes having the sequence of SEQ ID NO: 666, the site indicated by an amino acid other than X at SEQ ID NO: 664 or 665 is important for binding to the IgE antibody of allergic patients. Therefore, in another preferred embodiment, when the antigen of Spot 2α contains mutations with respect to the amino acid sequence of SEQ ID NO: 106, the antigen may be such that amino acids 51 to 65 in SEQ ID NO: 106 are the amino acid sequences of SEQ ID NO: 664 or 665.

[0074] Among the epitopes having the sequence of SEQ ID NO: 669, the site indicated by an amino acid other than X at SEQ ID NO: 667 or 668 is important for binding to the IgE antibody of allergic patients. Therefore, in another preferred embodiment, when the antigen of Spot 2α contains mutations with respect to the amino acid sequence of SEQ ID NO: 106, the antigen may be such that amino acids 69 to 73 in SEQ ID NO: 106 are the amino acid sequences of SEQ ID NO: 667 or 668.

[0075] Among the epitopes having the sequence of SEQ ID NO: 675, the site indicated by an amino acid other than X at SEQ ID NO: 673 or 674 is important for binding to the IgE antibody of allergic patients. Therefore, in another preferred embodiment, when the antigen of Spot 2α contains mutations with respect to the amino acid sequence of SEQ ID NO: 106, the antigen may be such that amino acids 411 to 425 in SEQ ID NO: 106 are the amino acid sequences of SEQ ID NO: 673 or 674.

[0076] Among the epitopes having the sequence of SEQ ID NO: 681, the site indicated by an amino acid other than X at SEQ ID NO: 679 or 680 is important for binding to the IgE antibody of an allergic patient. Therefore, in another preferred embodiment, when the antigen of spot 2α contains a mutation with respect to the amino acid sequence of SEQ ID NO: 106, the antigen may be such that amino acids 41 - 55 at SEQ ID NO: 106 are the amino acid sequence of SEQ ID NO: 679 or 680.

[0077] Among the epitopes having the sequence of SEQ ID NO: 684, the site indicated by an amino acid other than X at SEQ ID NO: 682 or 685 is important for binding to the IgE antibody of an allergic patient. Therefore, in another preferred embodiment, when the antigen of spot 2α contains a mutation with respect to the amino acid sequence of SEQ ID NO: 106, the antigen may be such that amino acids 451 - 465 at SEQ ID NO: 106 are the amino acid sequence of SEQ ID NO: 682 or 685.

[0078] Among the epitopes having the sequence of SEQ ID NO: 689, the site indicated by an amino acid other than X at SEQ ID NO: 688 is important for binding to the IgE antibody of an allergic patient. Therefore, in another preferred embodiment, when the antigen of spot 2α contains a mutation with respect to the amino acid sequence of SEQ ID NO: 106, the antigen may be such that amino acids 271 - 285 at SEQ ID NO: 106 are the amino acid sequence of SEQ ID NO: 688.

[0079] Preferably, the protein that is the antigen of spot 2α has the same activity as the protein having the amino acid sequence of SEQ ID NO: 106 (heat shock cognate protein 80), the protein having the amino acid sequence of SEQ ID NO: 122 (heat shock protein 90 - 1), or the protein having the amino acids of SEQ ID NO: 139 (hypothetical protein GLYMA_02G302500), or causes allergy to soybeans.

[0080] (4α) Spot 4α antigen Mass spectrometry analysis of spot 4α revealed the amino acid sequences of sequence numbers 156 and 157.

[0081] Furthermore, when the mass data obtained from the mass spectrometer for spot 4α was compared with NCBI's protein data and analyzed, embryo-specific urease isoform X1 (amino acid sequence: SEQ ID NO: 155, encoding nucleotide sequence: SEQ ID NO: 154) was identified as a protein containing either SEQ ID NO: 156 or 157.

[0082] Therefore, in this application, the antigen of spot 4α may be any protein selected from the group consisting of (4αA-a) to (4αA-e) and (4αB). (4αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 155. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (4αA-b)Sequence ID 155. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (4αA-c)Sequence ID 154. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (4αA-d)Sequence ID 154, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (4αA-e)Sequence ID 154. (4αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 156 and 157, preferably a protein comprising both of said amino acid sequences. Herein, the amino acid sequence represented by either SEQ ID NO: 156 or 157 may have one or more amino acids deleted, substituted, inserted, or added.

[0083] The protein selected from the group consisting of (4αA-a) to (4αA-e) and (4αB) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 70 to 120 kDa, preferably around 80 to 110 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0.

[0084] Furthermore, the epitopes of the spot 4α antigen are located at amino acids 121-130 (sequence number 719), 289-295 (sequence number 722), 293-302 (sequence number 725), 501-515 (sequence number 726), 571-585 (sequence number 727), 591-605 (sequence number 728), and 771-785 (sequence number 731) of sequence number 155. The spot 4α antigen may retain the sequence of sequence number 155 for amino acids at a position corresponding to at least one region of the epitope.

[0085] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy individuals are not judged as positive), the spot 4α antigen may also be one of the following variants.

[0086] Of the epitopes having the sequence of SEQ ID NO: 719, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 717 or 718. Therefore, in another preferred embodiment, the antigen of spot 4α may be such that amino acids 121-130 in SEQ ID NO: 155 are the amino acid sequence of SEQ ID NO: 717 or 718.

[0087] Of the epitopes having the sequence of SEQ ID NO: 722, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 720 or 721. Therefore, in another preferred embodiment, the spot 4α antigen may have amino acids 289-295 in SEQ ID NO: 155 being the amino acid sequence of SEQ ID NO: 720 or 721.

[0088] Of the epitopes having the sequence of SEQ ID NO: 725, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 723 or 724. Therefore, in another preferred embodiment, the antigen of spot 4α may be such that amino acids 293-302 in SEQ ID NO: 155 are the amino acid sequence of SEQ ID NO: 723 or 724.

[0089] Of the epitopes having the sequence of SEQ ID NO: 731, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 729 or 730. Therefore, in another preferred embodiment, the antigen of spot 4α may be such that amino acids 771-785 in SEQ ID NO: 155 are the amino acid sequence of SEQ ID NO: 729 or 730.

[0090] Preferably, the antigen protein of spot 4α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 155 (embryo-specific urease isoform X1), or is the cause of allergy to soy.

[0091] (5α) Spot 5α antigen Mass spectrometry analysis of spot 5α revealed the amino acid sequences of sequence numbers 160 and 161.

[0092] Regarding spot 5α, when the mass data obtained from the mass spectrometer was compared with the protein data of NCBI and analyzed, α-1,4 glucan phosphorylase L isozyme, chloroplastic / amyloplastic (alpha-1,4 glucan phosphorylase L isozyme, chloroplastic / amyloplastic) (amino acid sequence: SEQ ID NO: 159, nucleotide sequence encoding the same: SEQ ID NO: 158), which contains either SEQ ID NO: 160 or 161, was identified.

[0093] Therefore, the antigen of spot 5α in the present application may be any protein selected from the group consisting of the following (5αA-a) to (5αA-e), and (5αB). (5αA-a) A protein containing an amino acid sequence in which one or several amino acids are deleted, substituted, inserted or added in SEQ ID NO: 159. (5αA-b) A protein containing an amino acid sequence having 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more identity with the amino acid sequence represented by SEQ ID NO: 159. (5αA-c) A protein containing an amino acid sequence encoded by a nucleotide sequence in which one or several nucleotides are deleted, substituted, inserted or added in SEQ ID NO: 158. (5αA-d) A protein containing an amino acid sequence encoded by a nucleotide sequence having 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more identity with the nucleotide sequence represented by SEQ ID NO: 158. (5αA-e) A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO: 158. (5αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 160 and 161, preferably a protein comprising both of said amino acid sequences. Herein, the amino acid sequence represented by either SEQ ID NO: 160 or 161 may have one or more amino acids deleted, substituted, inserted, or added.

[0094] The protein selected from the group consisting of (5αA-a) to (5αA-e) and (5αB) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 70 to 170 kDa, preferably around 80 to 160 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0.

[0095] Furthermore, the epitopes of the spot 5α antigen are located at amino acids 861-875 (sequence number 734), 871-885 (sequence number 735), 891-905 (sequence number 736), 901-915 (sequence number 737), and 951-965 (sequence number 738) of sequence number 159. The spot 5α antigen may retain the sequence of sequence number 159 for amino acids at a position corresponding to at least one region of the epitope.

[0096] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be identified as positive) and specificity (the degree to which healthy individuals are not identified as positive), the spot 5α antigen may also be one of the following variants.

[0097] Of the epitopes having the sequence of SEQ ID NO: 734, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 732 or 733. Therefore, in another preferred embodiment, the spot 5α antigen may be such that amino acids 861-875 in SEQ ID NO: 159 are the amino acid sequence of SEQ ID NO: 732 or 733.

[0098] Preferably, the antigen protein of spot 5α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 159 (alpha-1,4 glucan phosphorylase L isozyme, chloroplastic / amyloplastic), or is the cause of allergy to soy.

[0099] (6α) Spot 6α antigen Mass spectrometry analysis of spot 6α revealed the amino acid sequences corresponding to sequence numbers 164-172.

[0100] Furthermore, when the mass data obtained from the mass spectrometer for spot 6α was compared with NCBI's protein data and analyzed, aconitate hydratase 1 (amino acid sequence: SEQ ID NO: 163, encoding nucleotide sequence: SEQ ID NO: 162) was identified as a protein containing one of SEQ ID NOs: 164-167, and aconitate hydratase 1 (amino acid sequence: SEQ ID NO: 169, encoding nucleotide sequence: SEQ ID NO: 168) was identified as a protein containing one of SEQ ID NOs: 170-172.

[0101] Therefore, in this application, the antigen of spot 6α may be any protein selected from the group consisting of (6αA1-a) to (6αA1-e), (6αB1), (6αA2-a) to (6αA2-e), and (6αB2). (6αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 163. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (6αA1-b)Sequence ID 163. (6αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 162. A protein comprising an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (6αA1-d)Sequence ID 162, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (6αA1-e)Sequence ID 162. (6αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 164-167, preferably a protein comprising at least two, three, or all of said amino acid sequences. Herein, the amino acid sequence represented by any of SEQ ID NOs: 164-167 may have one or more amino acids deleted, substituted, inserted, or added. (6αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 169. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (6αA2-b)Sequence ID 169. (6αA2-c) A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 168. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (6αA2-d)Sequence ID 168, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (6αA2-e)Sequence ID 168. (6αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 170-172, preferably a protein comprising at least two or all of said amino acid sequences. Herein, the amino acid sequence represented by any of SEQ ID NOs: 170-172 may have one or more amino acids deleted, substituted, inserted, or added.

[0102] Proteins selected from the group consisting of (6αA1-a) to (6αA1-e), (6αB1), (6αA2-a) to (6αA2-e), and (6αB2) may appear as spots on a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 70 to 120 kDa, preferably around 80 to 110 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0.

[0103] Furthermore, the epitopes of the antigens (6αA1-a) to (6αA1-e) and (6αB1) are located at amino acids 761-775 (sequence number 739) and 831-845 (sequence number 740) of sequence number 163. If the spot 6α antigen contains mutations in the amino acid sequence of sequence number 163, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence of sequence number 163.

[0104] Preferably, the antigen protein of spot 6α has activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 163 or 169 (aconitate hydratase 1), or is the cause of allergy to soy.

[0105] (7α) Spot 7α antigen Mass spectrometry analysis of spot 7α revealed the amino acid sequences corresponding to sequence numbers 175-187.

[0106] Furthermore, when the mass data obtained from the mass spectrometer for spot 7α was compared with NCBI's protein data and analyzed, methionine synthase (amino acid sequence: SEQ ID NO: 174, encoding nucleotide sequence: SEQ ID NO: 173) was identified as a protein containing one of SEQ ID NOs: 175-187.

[0107] Therefore, in this application, the antigen of spot 7α may be any protein selected from the group consisting of (7αA-a) to (7αA-e) and (7αB). (7αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 174. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (7αA-b)Sequence ID 174. (7αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 173. A protein comprising an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (7αA-d)Sequence ID 173, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleic acid sequence complementary to the base sequence shown in (7αA-e)Sequence ID 173. (7αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 175-187, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs: 175-187 may have one or more amino acids deleted, substituted, inserted, or added.

[0108] The protein selected from the group consisting of (7αA-a) to (7αA-e) and (7αB) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 50 to 120 kDa, preferably around 60 to 110 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0.

[0109] Furthermore, the epitope of the spot 7α antigen is located at amino acids 471-485 (sequence number 741) and 581-595 (sequence number 744) of sequence number 174. The spot 7α antigen may retain the sequence in sequence number 174 for amino acids at a position corresponding to at least one region of the epitope.

[0110] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy individuals are not judged as positive), the spot 7α antigen may also be one of the following variants.

[0111] Of the epitopes having the sequence of SEQ ID NO: 744, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 742 or 743. Therefore, in another preferred embodiment, the antigen of spot 7α may be such that amino acids 581-595 in SEQ ID NO: 174 are the amino acid sequence of SEQ ID NO: 742 or 743.

[0112] Preferably, the antigen protein of spot 7α has activity equivalent to that of the protein (methionine synthase) having the amino acid sequence of SEQ ID NO: 174, or is the cause of allergy to soy.

[0113] (8α) Spot 8α antigen Mass spectrometry analysis of spot 8α revealed the amino acid sequences corresponding to sequence numbers 190-199.

[0114] Furthermore, when the mass data obtained from the mass spectrometer for spot 8α was compared with NCBI's protein data and analyzed, transketolase, chloroplastic (amino acid sequence: sequence number 189, encoding nucleotide sequence: sequence number 188) was identified as a protein containing one of sequence numbers 190-199.

[0115] Therefore, in this application, the antigen of spot 8α may be any protein selected from the group consisting of (8αA-a) to (8αA-e) and (8αB). (8αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 189. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (8αA-b)Sequence ID 189. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (8αA-c)Sequence ID 188. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (8αA-d)Sequence ID 188, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (8αA-e)Sequence ID 188. (8αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 190-199, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs: 190-199 may have one or more amino acids deleted, substituted, inserted, or added.

[0116] The protein selected from the group consisting of (8αA-a) to (8αA-e) and (8αB) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 50 to 120 kDa, preferably around 60 to 110 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0.

[0117] Preferably, the antigen protein of spot 8α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 189 (transketolase, chloroplastic), or is the cause of allergy to soy.

[0118] (9α) Spot 9α antigen Mass spectrometry analysis of spot 9α revealed the amino acid sequence of sequence number 202.

[0119] Furthermore, when the mass data obtained from the mass spectrometer for spot 9α was compared with NCBI's protein data and analyzed, lysine-tRNA ligase, cytoplasmic-like isoform X2 (amino acid sequence: SEQ ID NO: 201, encoding nucleotide sequence: SEQ ID NO: 200) was identified as a protein containing SEQ ID NO: 202.

[0120] Therefore, in this application, the antigen of spot 9α may be any protein selected from the group consisting of (9αA-a) to (9αA-e) and (9αB). (9αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 201. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (9αA-b)Sequence ID 201. (9αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 200. A protein comprising an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (9αA-d)Sequence ID 200, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (9αA-e)Sequence ID 200. (9αB) A protein containing the amino acid sequence shown in SEQ ID NO: 202. Herein, the amino acid sequence shown in SEQ ID NO: 202 may have one or more amino acids deleted, substituted, inserted, or added.

[0121] The protein selected from the group consisting of (9αA-a) to (9αA-e) and (9αB) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 50 to 120 kDa, preferably around 60 to 110 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0.

[0122] Furthermore, the epitope of the spot 9α antigen is located at amino acids 236-245 (sequence number 747) and 283-290 (sequence number 749) of sequence number 201. The spot 9α antigen may retain the sequence of sequence number 201 for amino acids at a position corresponding to at least one region of the epitope.

[0123] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be identified as positive) and specificity (the degree to which healthy individuals are not identified as positive), the spot9α antigen may also be one of the following variants.

[0124] Of the epitopes having the sequence of SEQ ID NO: 747, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 745 or 746. Therefore, in another preferred embodiment, the spot 9α antigen may be such that amino acids 236-245 in SEQ ID NO: 201 are the amino acid sequence of SEQ ID NO: 745 or 746.

[0125] Of the epitopes having the sequence of SEQ ID NO: 749, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 748. Therefore, in another preferred embodiment, the antigen of spot 9α may be such that amino acids 283-290 in SEQ ID NO: 201 are the amino acid sequence of SEQ ID NO: 748.

[0126] Preferably, the antigen protein of spot 9α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 201 (lysine-tRNA ligase, cytoplasmic-like isoform X2), or is the cause of allergy to soy.

[0127] (10α) Spot 10α antigen Mass spectrometry analysis of spot 10α revealed the amino acid sequences corresponding to sequence numbers 205-231.

[0128] Furthermore, when the mass data obtained from the mass spectrometer for spot 10α was compared with NCBI's protein data and analyzed, chaperonin CPN60-2, mitochondrial (amino acid sequence: SEQ ID NO: 204, encoding nucleotide sequence: SEQ ID NO: 203) was identified as a protein containing one of SEQ ID NOs. 205-218, and chaperonin CPN60-2, mitochondrial-like isoform X1 (amino acid sequence: SEQ ID NO: 220, encoding nucleotide sequence: SEQ ID NO: 219) was identified as a protein containing one of SEQ ID NOs. 221-231.

[0129] Therefore, in this application, the antigen of spot 10α may be any protein selected from the group consisting of (10αA1-a) to (10αA1-e), (10αB1), (10αA2-a) to (10αA2-e), and (10αB2). (10αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 204. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (10αA1-b)Sequence ID 204. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (10αA1-c)Sequence ID 203. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (10αA1-d)Sequence ID 203, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (10αA1-e)Sequence Number 203. (10αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 205 to 218, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 205 to 218 may have one or more amino acids deleted, substituted, inserted, or added. (10αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 220. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (10αA2-b)Sequence ID 220. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (10αA2-c)Sequence ID 219. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (10αA2-d)Sequence ID 219, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (10αA2-e)SEQ ID NO: 219. (10αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 221-231, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 221-231 may have one or more amino acids deleted, substituted, inserted, or added.

[0130] Proteins selected from the group consisting of (10αA1-a) to (10αA1-e), (10αB1), (10αA2-a) to (10αA2-e), and (10αB2) may appear as spots with a molecular weight of 30 to 90 kDa, preferably around 40 to 80 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0131] Preferably, the antigen protein of spot 10α has activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 204 (haperonin CPN60-2, mitochondrial) or a protein having the amino acid sequence of SEQ ID NO: 220 (chaperonin CPN60-2, mitochondrial-like isoform X1), or is the cause of allergy to soy.

[0132] (11α) Spot 11α antigen Mass spectrometry analysis of spot 11α revealed the amino acid sequences corresponding to sequence numbers 234-237.

[0133] Furthermore, when the mass data obtained from the mass spectrometer for spot 11α was compared with NCBI's protein data and analyzed, polyadenylate-binding protein 8 isoform X3 (amino acid sequence: SEQ ID NO: 233, encoding nucleotide sequence: SEQ ID NO: 232) was identified as a protein containing one of SEQ ID NOs: 234-237.

[0134] Therefore, in this application, the antigen of spot 11α may be any protein selected from the group consisting of (11αA-a) to (11αA-e) and (11αB). (11αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 233. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (11αA-b)Sequence ID 233. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (11αA-c)Sequence ID 232. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (11αA-d)Sequence ID 232, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (11αA-e)Sequence Number 232. (11αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 234 to 237, preferably a protein comprising at least two, three, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 234 to 237 may have one or more amino acids deleted, substituted, inserted, or added.

[0135] The protein selected from the group consisting of (11αA-a) to (11αA-e) and (11αB) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 30 to 90 kDa, preferably around 40 to 80 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0.

[0136] Furthermore, the epitope of the spot 11α antigen is located at amino acids 454-463 (sequence number 753) and 363-370 (sequence number 754) of sequence number 233. The spot 11α antigen may retain the sequence in sequence number 233 for amino acids at a position corresponding to at least one region of the epitope.

[0137] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy individuals are not judged as positive), the antigen of spot 11α may also be one of the following variants.

[0138] Of the epitopes having the sequence of SEQ ID NO: 753, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 751 or 752. Therefore, in another preferred embodiment, the antigen of spot 11α may be such that amino acids 454-463 in SEQ ID NO: 223 are the amino acid sequence of SEQ ID NO: 751 or 752.

[0139] Preferably, the antigen protein of spot 11α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 233 (polyadenylate-binding protein 8 isoform X3), or is the cause of allergy to soy.

[0140] (12α) Spot 12α antigen Mass spectrometry analysis of spot 12α revealed the amino acid sequence of sequence number 240.

[0141] Furthermore, when the mass data obtained from the mass spectrometer for spot 12α was compared with NCBI's protein data and analyzed, the protein containing sequence number 240 was identified as pyrophosphate-fructose 6-phosphate 1-phosphotransferase subunit alpha-like (amino acid sequence: sequence number 239, encoding nucleotide sequence: sequence number 238).

[0142] Therefore, in this application, the antigen of spot 12α may be any protein selected from the group consisting of (12αA-a) to (12αA-e) and (12αB). (12αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 239. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (12αA-b)Sequence ID 239. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (12αA-c)Sequence ID 238. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (12αA-d)Sequence ID 238, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (12αA-e)Sequence No. 238. (12αB) A protein containing the amino acid sequence shown in SEQ ID NO: 240. Herein, the amino acid sequence shown in SEQ ID NO: 240 may have one or more amino acids deleted, substituted, inserted, or added.

[0143] The protein selected from the group consisting of (12αA-a) to (12αA-e) and (12αB) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 30 to 90 kDa, preferably around 40 to 80 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0.

[0144] Furthermore, the epitope of the spot 12α antigen is located at amino acids 551-565 (sequence number 755) of sequence number 239. The spot 11α antigen may retain the sequence of sequence number 239 for the amino acids at the position corresponding to the epitope region.

[0145] Preferably, the antigen protein of spot 12α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 239 (pyrophosphate--fructose 6-phosphate 1-phosphotransferase subunit alpha-like), or is the cause of allergy to soy.

[0146] (13α) Spot 13α antigen Mass spectrometry analysis of spot 13α revealed the amino acid sequences corresponding to sequence numbers 243-278.

[0147] Furthermore, when the mass data obtained from the mass spectrometer for spot 13α was compared with NCBI's protein data and analyzed, a protein disulfide isomerase-like protein precursor (amino acid sequence: SEQ ID NO: 242, encoding nucleotide sequence: SEQ ID NO: 241) was identified as a protein containing one of SEQ ID NOs: 243-252, and a protein disulfide-isomerase (amino acid sequence: SEQ ID NO: 254, encoding nucleotide sequence: SEQ ID NO: 253) was identified as a protein containing one of SEQ ID NOs: 255-278.

[0148] Therefore, in this application, the antigen of spot 13α may be any protein selected from the group consisting of (13αA1-a) to (13αA1-e), (13αB1), (13αA2-a) to (13αA2-e), and (13αB2). (13αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 242. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (13αA1-b)Sequence ID 242. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (13αA1-c)Sequence ID 241. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (13αA1-d)Sequence ID 241, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (13αA1-e)Sequence ID 241. (13αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 243 to 252, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 205 to 218 may have one or more amino acids deleted, substituted, inserted, or added. (13αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 254. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (13αA2-b)Sequence ID 254. A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (13αA2-c)Sequence ID 253. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (13αA2-d)Sequence ID 253, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (13αA2-e)SEQ ID NO: 253. (13αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 255 to 278, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 221 to 231 may have one or more amino acids deleted, substituted, inserted, or added.

[0149] Proteins selected from the group consisting of (13αA1-a) to (13αA1-e), (13αB1), (13αA2-a) to (13αA2-e), and (13αB2) may appear as spots with a molecular weight of 30 to 90 kDa, preferably around 40 to 80 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0150] Furthermore, the epitopes of the antigens (13αA1-a) to (13αA1-e) and (13αB1) are located at amino acids 471 to 485 (sequence number 758) of sequence number 242. If the antigen of spot 13α contains a mutation in the amino acid sequence of sequence number 242, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence in sequence number 242.

[0151] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be identified as positive) and specificity (the degree to which healthy individuals are not identified as positive), the spot 13α antigen may also be one of the following variants.

[0152] Of the epitopes having the sequence of SEQ ID NO: 758, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 756 or 757. Therefore, in another preferred embodiment, if the antigen of spot 13α contains a mutation in the amino acid sequence of SEQ ID NO: 242, then the antigen may have amino acids 471-485 in SEQ ID NO: 242 being the amino acid sequence of SEQ ID NO: 756 or 757.

[0153] Preferably, the antigen protein of spot 13α has activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 242 (protein disulfide isomerase-like protein precursor) or a protein having the amino acid sequence of SEQ ID NO: 254 (protein disulfide-isomerase), or is the cause of allergy to soy.

[0154] (14α) Spot 14α antigen Mass spectrometry analysis of spot 14α revealed the amino acid sequences corresponding to sequence numbers 281-289.

[0155] Furthermore, when the mass data obtained from the mass spectrometer for spot 14α was compared with NCBI's protein data and analyzed, V-type proton ATPase subunit B2 (amino acid sequence: SEQ ID NO: 280, encoding nucleotide sequence: SEQ ID NO: 279) was identified as a protein containing one of SEQ ID NOs. 281-284, and V-type proton ATPase subunit B2 (amino acid sequence: SEQ ID NO: 286, encoding nucleotide sequence: SEQ ID NO: 285) was identified as a protein containing one of SEQ ID NOs. 287-289.

[0156] Therefore, in this application, the antigen of spot 14α may be any protein selected from the group consisting of (14αA1-a) to (14αA1-e), (14αB1), (14αA2-a) to (14αA2-e), and (14αB2). (14αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 280. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (14αA1-b)Sequence ID 280. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (14αA1-c)Sequence ID 279. A protein comprising an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (14αA1-d)Sequence ID 279, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (14αA1-e)SEQ ID NO: 279. (14αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 281 to 284, preferably a protein comprising at least two, three, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 281 to 284 may have one or more amino acids deleted, substituted, inserted, or added. (14αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 286. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (14αA2-b)Sequence ID 286. A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (14αA2-c)Sequence ID 285. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (14αA2-d)Sequence ID 285, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (14αA2-e)SEQ ID NO: 285. (14αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 287 to 289, preferably a protein comprising at least two or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 287 to 289 may have one or more amino acids deleted, substituted, inserted, or added.

[0157] Proteins selected from the group consisting of (14αA1-a) to (14αA1-e), (14αB1), (14αA2-a) to (14αA2-e), and (14αB2) may appear as spots with a molecular weight of 30 to 90 kDa, preferably around 40 to 80 kDa, and an isoelectric point of 2.5 to 6.5, preferably 3.0 to 6.0, on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0158] Furthermore, the epitopes of the antigens (14αA1-a) to (14αA1-e) and (14αB1) are located at amino acids 191-205 (sequence number 761) and 391-405 (sequence number 764) of sequence number 280. If the antigen of spot 14α contains a mutation in the amino acid sequence of sequence number 280, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence in sequence number 280.

[0159] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be identified as positive) and specificity (the degree to which healthy individuals are not identified as positive), the spot14α antigen may also be one of the following variants.

[0160] Of the epitopes having the sequence of SEQ ID NO: 761, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 759 or 760. Therefore, in another preferred embodiment, if the antigen of spot 14α contains a mutation in the amino acid sequence of SEQ ID NO: 280, then the antigen may have amino acids 191-205 in SEQ ID NO: 280 independently corresponding to the amino acid sequences of SEQ ID NO: 759 or 760.

[0161] Of the epitopes having the sequence of SEQ ID NO: 764, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 762 or 763. Therefore, in another preferred embodiment, if the antigen of spot 14α contains a mutation in the amino acid sequence of SEQ ID NO: 280, then the antigen may have amino acids 391-405 in SEQ ID NO: 280 independently corresponding to the amino acid sequences of SEQ ID NO: 762 or 763.

[0162] Preferably, the antigen protein of spot 14α has activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 280 or 286 (V-type proton ATPase subunit B 2), or is the cause of allergy to soy.

[0163] (15α, 16α) Spot 15α, 16α antigens Mass spectrometry analysis of spots 15α and 16α revealed the amino acid sequences corresponding to sequence numbers 292-318.

[0164] Furthermore, when the mass data obtained from the mass spectrometer for spots 15α and 16α were compared with NCBI's protein data and analyzed, UTP-glucose-1-phosphate uridylyltransferase (amino acid sequence: SEQ ID NO: 291, encoding nucleotide sequence: SEQ ID NO: 290) was identified as a protein containing one of SEQ ID NOs. 302-304, and hypothetical protein GLYMA_02G241100 (amino acid sequence: SEQ ID NO: 306, encoding nucleotide sequence: SEQ ID NO: 305) was identified as a protein containing one of SEQ ID NOs. 307-318.

[0165] Therefore, in this application, the antigens of spots 15α and 16α may be any protein selected from the group consisting of (15,16αA1-a) to (15,16αA1-e), (15,16αB1), (15,16αA2-a) to (15,16αA2-e), and (15,16αB2). (15,16αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 291. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (15,16αA1-b)Sequence ID 291. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (15,16αA1-c)Sequence ID 290. A protein comprising an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (15,16αA1-d)Sequence ID 290, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (15,16αA1-e)Sequence ID 290. (15,16αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 292-304, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 292-304 may have one or more amino acids deleted, substituted, inserted, or added. (15,16αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 306. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (15,16αA2-b)Sequence ID 306. (15.16αA2-c) A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 305. (15,16αA2-d) A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in SEQ ID NO: 305, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. (15,16αA2-e) A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 305. (15,16αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 307 to 318, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 307 to 318 may have one or more amino acids deleted, substituted, inserted, or added.

[0166] Proteins selected from the group consisting of (15,16αA1-a) to (15,16αA1-e), (15,16αB1), (15,16αA2-a) to (15,16αA2-e), and (15,16αB2) may appear as spots with a molecular weight of 20 to 90 kDa, preferably around 30 to 80 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0167] Furthermore, the epitopes of the antigens (15,16αA1-a) to (15,16αA1-e) and (15,16αB1) are located at amino acids 211 to 225 of SEQ ID NO: 291 (SEQ ID NO: 766). If the antigens of spots 15α and 16α contain mutations in the amino acid sequence of SEQ ID NO: 291, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence in SEQ ID NO: 291.

[0168] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy individuals are not judged as positive), the spot 15α and 16α antigens may also be the following variants.

[0169] Of the epitopes having the sequence of SEQ ID NO: 766, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 765. Therefore, in another preferred embodiment, if the antigen of spot 15α,16α contains a mutation in the amino acid sequence of SEQ ID NO: 291, then the antigen may have amino acids 211-225 in SEQ ID NO: 291 being the amino acid sequence of SEQ ID NO: 765.

[0170] Preferably, the antigen proteins of spots 15α and 16α have activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 291 (UTP-glucose-1-phosphate uridylyltransferase) or the protein having the amino acid sequence of SEQ ID NO: 306 (hypothetical protein GLYMA_02G241100), or are the cause of allergy to soy.

[0171] (17α) Spot 17α antigen Mass spectrometry analysis of spot 17α revealed the amino acid sequence corresponding to sequence numbers 321-332.

[0172] Furthermore, when the mass data obtained from the mass spectrometer for spot 17α was compared with NCBI's protein data and analyzed, guanosine nucleotide diphosphate dissociation inhibitor 2 (amino acid sequence: SEQ ID NO: 320, encoding nucleotide sequence: SEQ ID NO: 319) was identified as a protein containing one of SEQ ID NOs: 321-325, and rab GDP dissociation inhibitor alpha-like (amino acid sequence: SEQ ID NO: 327, encoding nucleotide sequence: SEQ ID NO: 326) was identified as a protein containing one of SEQ ID NOs: 328-332.

[0173] Therefore, in this application, the antigen of spot 17α may be any protein selected from the group consisting of (17αA1-a) to (17αA1-e), (17αB1), (17αA2-a) to (17αA2-e), and (17αB2). (17αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 320. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (17αA1-b)Sequence ID 320. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (17αA1-c)Sequence ID 319. A protein comprising an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (17αA1-d)Sequence ID 319, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (17αA1-e)Sequence ID 319. (17αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 321 to 325, preferably a protein comprising at least two, three, four, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 321 to 325 may have one or more amino acids deleted, substituted, inserted, or added. (17αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 327. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (17αA2-b)Sequence ID 327. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (17αA2-c)Sequence ID 326. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (17αA2-d)Sequence ID 326, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (17αA2-e)Sequence ID 326. (17αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 328 to 332, preferably a protein comprising at least two, three, four, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 328 to 332 may have one or more amino acids deleted, substituted, inserted, or added.

[0174] The protein selected from the group consisting of (17αA1-a) to (17αA1-e), (17αB1), (17αA2-a) to (17αA2-e), and (17αB2) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 20 to 90 kDa, preferably around 30 to 80 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0.

[0175] Furthermore, the epitopes of the antigens (17αA1-a) to (17αA1-e) and (17αB1) are located at amino acids 171 to 185 of SEQ ID NO: 320 (SEQ ID NO: 767). If the antigen of spot 17α contains a mutation in the amino acid sequence of SEQ ID NO: 320, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence in SEQ ID NO: 320.

[0176] Preferably, the antigen protein of spot 17α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 320 (guanosine nucleotide diphosphate dissociation inhibitor 2) or the protein having the amino acid sequence of SEQ ID NO: 327 (rab GDP dissociation inhibitor alpha-like), or is the cause of allergy to soy.

[0177] (18α) Spot 18α antigen Mass spectrometry analysis of spot 18α revealed the amino acid sequences corresponding to sequence numbers 335-339.

[0178] Furthermore, when the mass data obtained from the mass spectrometer for spot 18α was compared with NCBI's protein data and analyzed, hypothetical protein GLYMA_10G028300 (amino acid sequence: SEQ ID NO: 334, encoding nucleotide sequence: SEQ ID NO: 333) was identified as a protein containing one of SEQ ID NOs: 335-339.

[0179] Therefore, in this application, the antigen of spot 18α may be any protein selected from the group consisting of (18αA-a) to (18αA-e) and (18αB). (18αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 334. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (18αA-b)Sequence ID 334. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (18αA-c)Sequence ID 333. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (18αA-d)Sequence ID 333, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (18αA-e)Sequence ID 333. (18αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 335 to 339, preferably a protein comprising at least two, three, four, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 335 to 339 may have one or more amino acids deleted, substituted, inserted, or added.

[0180] The protein selected from the group consisting of (18αA-a) to (18αA-e) and (18αB) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 30 to 90 kDa, preferably around 40 to 80 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0.

[0181] Furthermore, the epitopes of the spot 18α antigen are located at amino acids 52-60 (sequence number 750), 81-95 (sequence number 768), 101-115 (sequence number 771), 281-295 (sequence number 772), and 491-500 (sequence number 775) of sequence number 334. The spot 18α antigen may retain the sequence in sequence number 334 for amino acids at a position corresponding to at least one region of the epitope.

[0182] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy individuals are not judged as positive), the spot18α antigen may also be one of the following variants.

[0183] Of the epitopes having the sequence of SEQ ID NO: 771, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 769 or 770. Therefore, in another preferred embodiment, the antigen of spot 18α may be such that amino acids 101-115 in SEQ ID NO: 334 are the amino acid sequence of SEQ ID NO: 769 or 770.

[0184] Of the epitopes having the sequence of SEQ ID NO: 775, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 773 or 774. Therefore, in another preferred embodiment, the antigen of spot 18α may be such that amino acids 491-500 in SEQ ID NO: 334 are the amino acid sequence of SEQ ID NO: 773 or 774.

[0185] Preferably, the antigen protein of spot 18α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 334 (hypothetical protein GLYMA_10G028300), or is the cause of allergy to soy.

[0186] (19α) Spot 19α antigen Mass spectrometry analysis of spot 19α revealed the amino acid sequences corresponding to sequence numbers 342-346.

[0187] Furthermore, when the mass data obtained from the mass spectrometer for spot 19α was compared with NCBI's protein data and analyzed, sucrose binding protein homolog S-64 (amino acid sequence: SEQ ID NO: 341, encoding nucleotide sequence: SEQ ID NO: 340) was identified as a protein containing one of SEQ ID NOs: 342-346.

[0188] Therefore, in this application, the antigen of spot 19α may be any protein selected from the group consisting of (19αA-a) to (19αA-e) and (19αB). (19αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 341. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (19αA-b)Sequence ID 341. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (19αA-c)Sequence ID 340. A protein comprising an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (19αA-d)Sequence ID 340, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (19αA-e)Sequence ID 340. (19αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 342 to 346, preferably a protein comprising at least two, three, four, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 342 to 346 may have one or more amino acids deleted, substituted, inserted, or added.

[0189] The protein selected from the group consisting of (19αA-a) to (19αA-e) and (19αB) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 30 to 90 kDa, preferably around 40 to 80 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0.

[0190] Furthermore, the epitopes of the spot 19α antigen are located at amino acids 191-205 (sequence number 778), 475-489 (sequence number 781), 81-95 (sequence number 784), 436-450 (sequence number 786), and 21-30 (sequence number 787) of sequence number 341. The spot 19α antigen may retain the sequence in sequence number 341 for amino acids at a position corresponding to at least one region of the epitope.

[0191] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be identified as positive) and specificity (the degree to which healthy individuals are not identified as positive), the spot19α antigen may also be one of the following variants.

[0192] Of the epitopes having the sequence of SEQ ID NO: 778, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 776 or 778. Therefore, in another preferred embodiment, the antigen of spot 19α may be such that amino acids 191-205 in SEQ ID NO: 341 are the amino acid sequence of SEQ ID NO: 776 or 778.

[0193] Of the epitopes having the sequence of SEQ ID NO: 781, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 779 or 780. Therefore, in another preferred embodiment, the antigen of spot 19α may be such that amino acids 475-489 in SEQ ID NO: 341 are the amino acid sequence of SEQ ID NO: 779 or 780.

[0194] Of the epitopes having the sequence of SEQ ID NO: 784, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 782 or 783. Therefore, in another preferred embodiment, the antigen of spot 19α may be such that amino acids 81-95 in SEQ ID NO: 341 are the amino acid sequence of SEQ ID NO: 782 or 783.

[0195] Preferably, the antigen protein of spot 19α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 341 (sucrose binding protein homolog S-64), or is the cause of allergy to soy.

[0196] (25α) Spot 25α antigen Mass spectrometry analysis of spot 25α revealed the amino acid sequences corresponding to sequence numbers 349-365.

[0197] Furthermore, when the mass data obtained from the mass spectrometer for spot 25α was compared with NCBI's protein data and analyzed, succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial (amino acid sequence: SEQ ID NO: 348, encoding nucleotide sequence: SEQ ID NO: 347) was identified as a protein containing one of SEQ ID NOs: 349-356, and succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial (amino acid sequence: SEQ ID NO: 358, encoding nucleotide sequence: SEQ ID NO: 357) was identified as a protein containing one of SEQ ID NOs: 359-365.

[0198] Therefore, in this application, the antigen of spot 25α may be any protein selected from the group consisting of (25αA1-a) to (25αA1-e), (25αB1), (25αA2-a) to (25αA2-e), and (25αB2). (25αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 348. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (25αA1-b)Sequence ID 348. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (25αA1-c)Sequence ID 347. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (25αA1-d)Sequence ID 347, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (25αA1-e)SEQ ID NO: 347. (25αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 349 to 356, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 349 to 356 may have one or more amino acids deleted, substituted, inserted, or added. (25αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 358. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (25αA2-b)Sequence ID 358. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (25αA2-c)Sequence ID 357. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (25αA2-d)Sequence ID 357, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (25αA2-e)SEQ ID NO: 357. (25αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 359 to 365, preferably a protein comprising at least 2, 3, 4, 5, 6, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 359 to 365 may have one or more amino acids deleted, substituted, inserted, or added.

[0199] Proteins selected from the group consisting of (25αA1-a) to (25αA1-e), (25αB1), (25αA2-a) to (25αA2-e), and (25αB2) may appear as spots with a molecular weight of 20 to 90 kDa, preferably around 30 to 80 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0200] Furthermore, the epitopes of the antigens (25αA1-a) to (25αA1-e) and (25αB1) are located at amino acids 241 to 255 (sequence number 814) and 321 to 335 (sequence number 815) of sequence number 348. If the antigen of spot 25α contains a mutation in the amino acid sequence of sequence number 348, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence in sequence number 348.

[0201] Preferably, the antigen protein of spot 25α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 348 or 358 (succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial), or is the cause of allergy to soy.

[0202] (26α) Spot 26α antigen Mass spectrometry analysis of spot 26α revealed the amino acid sequence corresponding to sequence numbers 368-409.

[0203] Furthermore, when the mass data obtained from the mass spectrometer for spot 26α was compared with NCBI's protein data and analyzed, the following proteins were identified: phosphoglycerate kinase, cytosolic (amino acid sequence: SEQ ID NO: 367, encoding nucleotide sequence: SEQ ID NO: 366) containing one of SEQ ID NOs: 385-392 containing phosphoglycerate kinase, cytosolic (amino acid sequence: SEQ ID NO: 384, encoding nucleotide sequence: SEQ ID NO: 383) containing one of SEQ ID NOs: 395-409 containing phosphoglycerate kinase, cytosolic (amino acid sequence: SEQ ID NO: 394, encoding nucleotide sequence: SEQ ID NO: 393).

[0204] Therefore, in this application, the antigen of spot 26α may be any protein selected from the group consisting of (26αA1-a) to (26αA1-e), (26αB1), (26αA2-a) to (26αA2-e), (26αB2), (26αA3-a) to (26αA3-e), and (26αB3). (26αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 367. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (26αA1-b)Sequence ID 367. (26αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 366. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (26αA1-d)Sequence ID 366, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (26αA1-e)Sequence ID 366. (26αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 368 to 382, ​​preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 368 to 382 may have one or more amino acids deleted, substituted, inserted, or added. (26αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 384. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (26αA2-b)Sequence ID 384. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (26αA2-c)Sequence ID 383. A protein comprising an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (26αA2-d)Sequence ID 383, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (26αA2-e)Sequence ID 383. (26αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 385 to 392, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 385 to 392 may have one or more amino acids deleted, substituted, inserted, or added. (26αA3-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 394. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (26αA3-b)Sequence ID 394. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (26αA3-c)Sequence ID 393. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (26αA3-d)Sequence ID 393, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (26αA3-e)Sequence ID 393. (26αB3) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 395 to 409, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 395 to 409 may have one or more amino acids deleted, substituted, inserted, or added.

[0205] Proteins selected from the group consisting of (26αA1-a)~(26αA1-e), (26αB1), (26αA2-a)~(26αA2-e), (26αB2), (26αA3-a)~(26αA3-e), and (26αB3) may appear as spots with a molecular weight of 20~90 kDa, preferably around 30~80 kDa, and an isoelectric point of 3.5~7.5, preferably 4.0~7.0, in the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigens" section above. Furthermore, the epitopes of the antigens (26αA1-a)~(26αA1-e) and (26αB1) are located at amino acids 121~135 (sequence number 816) and 329~335 (sequence number 819) of sequence number 367. If the antigen of spot 26α contains a mutation in the amino acid sequence of sequence number 367, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence of sequence number 361.

[0206] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be identified as positive) and specificity (the degree to which healthy individuals are not identified as positive), the spot26α antigen may also be one of the following variants.

[0207] Of the epitopes having the sequence of SEQ ID NO: 819, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 817 or 818. Therefore, in another preferred embodiment, if the antigen of spot 26α contains a mutation in the amino acid sequence of SEQ ID NO: 367, then the antigen may have amino acids 329-335 in SEQ ID NO: 367 being the amino acid sequence of SEQ ID NO: 817 or 818.

[0208] Preferably, the antigen protein of spot 25α has activity equivalent to that of a protein (phosphoglycerate kinase, cytosolic) having the amino acid sequence of SEQ ID NO: 367, 384, or 394, or is the cause of allergy to soy.

[0209] (27α) Spot 27α antigen Mass spectrometry analysis of spot 27α revealed the amino acid sequence corresponding to sequence numbers 412-427.

[0210] Furthermore, when the mass data obtained from the mass spectrometer for spot 27α was compared with NCBI's protein data and analyzed, the following proteins were identified: alcohol dehydrogenase 1 (amino acid sequence: SEQ ID NO: 411, encoding nucleotide sequence: SEQ ID NO: 410) containing one of SEQ ID NOs: 412-416; alcohol dehydrogenase 1 (amino acid sequence: SEQ ID NO: 418, encoding nucleotide sequence: SEQ ID NO: 417) containing one of SEQ ID NOs: 419 or 420; and alcohol dehydrogenase 1-like (amino acid sequence: SEQ ID NO: 422, encoding nucleotide sequence: SEQ ID NO: 421) containing one of SEQ ID NOs: 423-427.

[0211] Therefore, in this application, the antigen of spot 27α may be any protein selected from the group consisting of (27αA1-a)~(27αA1-e), (27αB1), (27αA2-a)~(27αA2-e), (27αB2), (27αA3-a)~(27αA3-e), and (27αB3). (27αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 411. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (27αA1-b)Sequence ID 411. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (27αA1-c)Sequence ID 410. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (27αA1-d)Sequence ID 410, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (27αA1-e)SEQ ID NO: 410. (27αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 412 to 416, preferably a protein comprising at least two, three, four, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 412 to 416 may have one or more amino acids deleted, substituted, inserted, or added. (27αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 418. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (27αA2-b)Sequence ID 418. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (27αA2-c)Sequence ID 417. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (27αA2-d)Sequence ID 417, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (27αA2-e)SEQ ID NO: 417. (27αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 419 and 420, preferably a protein comprising both of said amino acid sequences. Herein, the amino acid sequence represented by either SEQ ID NOs. 419 or 420 may have one or more amino acids deleted, substituted, inserted, or added. (27αA3-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 422. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (27αA3-b)Sequence ID 422. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (27αA3-c)Sequence ID 421. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (27αA3-d)Sequence ID 421, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (27αA3-e)SEQ ID NO: 421. (27αB3) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 423 to 427, preferably a protein comprising at least two, three, four, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 423 to 427 may have one or more amino acids deleted, substituted, inserted, or added.

[0212] Proteins selected from the group consisting of (27αA1-a) to (27αA1-e), (27αB1), (27αA2-a) to (27αA2-e), (27αB2), (27αA3-a) to (27αA3-e), and (27αB3) may appear as spots with a molecular weight of 20 to 90 kDa, preferably around 30 to 80 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0213] Furthermore, the epitopes of the antigens (27αA1-a) to (27αA1-e) and (27αB1) are located at amino acids 21 to 35 of SEQ ID NO: 411 (SEQ ID NO: 820). If the antigen of spot 27α contains a mutation in the amino acid sequence of SEQ ID NO: 411, the amino acids at the position corresponding to the region of the epitope may retain the sequence of SEQ ID NO: 411.

[0214] Preferably, the antigen protein of spot 27α has activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 411 or 418 (alcohol dehydrogenase 1) or a protein having the amino acid sequence of SEQ ID NO: 422 (alcohol dehydrogenase 1-like), or is the cause of allergy to soy.

[0215] (28α) Spot 28α antigen Mass spectrometry analysis of spot 28α revealed the amino acid sequence corresponding to sequence numbers 430-433.

[0216] Furthermore, when the mass data obtained from the mass spectrometer for spot 28α was compared with NCBI's protein data and analyzed, 35 kDa seed mutation protein isoform X1 (amino acid sequence: SEQ ID NO: 429, encoding nucleotide sequence: SEQ ID NO: 428) was identified as a protein containing one of SEQ ID NOs: 430-433.

[0217] Therefore, in this application, the antigen of spot 28α may be any protein selected from the group consisting of (28αA-a) to (28αA-e) and (28αB). (28αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 429. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (28αA-b)Sequence ID 429. (28αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in sequence number 428. A protein comprising an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (28αA-d)Sequence ID 428, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (28αA-e)Sequence ID 428. (28αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 430-433, preferably a protein comprising at least two, three, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs: 430-433 may have one or more amino acids deleted, substituted, inserted, or added.

[0218] The protein selected from the group consisting of (28αA-a) to (28αA-e) and (28αB) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 10 to 70 kDa, preferably around 20 to 60 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0.

[0219] Furthermore, the epitopes of the spot 28α antigen are located at amino acids 76-85 (sequence number 820), 191-205 (sequence number 826), 231-245 (sequence number 829), 111-125 (sequence number 830), 131-145 (sequence number 831), 161-175 (sequence number 832), 181-195 (sequence number 833), 291-305 (sequence number 834), and 295-309 (sequence number 835) of sequence number 429. The spot 28α antigen may retain the sequence of sequence number 429 for amino acids at a position corresponding to at least one region of the epitope.

[0220] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy individuals are not judged as positive), the spot28α antigen may also be one of the following variants.

[0221] Of the epitopes having the sequence of SEQ ID NO: 823, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 821 or 822. Therefore, in another preferred embodiment, the antigen of spot 28α may be such that amino acids 76-85 in SEQ ID NO: 429 are the amino acid sequence of SEQ ID NO: 821 or 822.

[0222] Of the epitopes having the sequence of SEQ ID NO: 826, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 824 or 825. Therefore, in another preferred embodiment, the antigen of spot 28α may be such that amino acids 191-205 in SEQ ID NO: 429 are the amino acid sequence of SEQ ID NO: 824 or 825.

[0223] Of the epitopes having the sequence of SEQ ID NO: 829, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 827 or 828. Therefore, in another preferred embodiment, the antigen of spot 28α may be such that amino acids 231-2455 in SEQ ID NO: 429 are the amino acid sequence of SEQ ID NO: 827 or 828.

[0224] Preferably, the antigen protein of spot 28α has activity equivalent to that of the protein having the amino acid sequence of sequence number 422 (35 kDa seed maturation protein isoform X1), or is the cause of allergy to soy.

[0225] (29α, 30α, 31α, 32α, 33α) Antigen spot 29α~33α Mass spectrometry analysis of spots 29α to 33α revealed the amino acid sequences corresponding to sequence numbers 436 to 451.

[0226] Furthermore, when the mass data obtained from the mass spectrometer for spots 27α to 33α were compared with NCBI's protein data and analyzed, the following proteins were identified: glyceraldehyde-3-phosphate dehydrogenase isoform X1 (amino acid sequence: SEQ ID NO: 435, encoding nucleotide sequence: SEQ ID NO: 434) containing one of SEQ ID NOs: 436 to 439; glyceraldehyde-3-phosphate dehydrogenase, cytosolic (amino acid sequence: SEQ ID NO: 441, encoding nucleotide sequence: SEQ ID NO: 440) containing one of SEQ ID NOs: 442 to 445; and uncharacterized protein LOC100782924 (amino acid sequence: SEQ ID NO: 447, encoding nucleotide sequence: SEQ ID NO: 446) containing one of SEQ ID NOs: 448 to 451.

[0227] Therefore, in this application, the antigens of spots 29α to 33α may be any protein selected from the group consisting of (29-33αA1-a) to (29-33αA1-e), (29-33αB1), (29-33αA2-a) to (29-33αA2-e), (29-33αB2), (29-33αA3-a) to (29-33αA3-e), and (29-33αB3). (29-33αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 435. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (29-33αA1-b)Sequence ID 435. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (29-33αA1-c)Sequence ID 434. (29-33αA1-d) A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the nucleotide sequence shown in SEQ ID NO: 434. (29-33αA1-e) A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 434. (29-33αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 436-439, preferably a protein comprising at least two, three, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 436-439 may have one or more amino acids deleted, substituted, inserted, or added. (29-33αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 441. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (29-33αA2-b)Sequence ID 441. (29-33αA2-c) A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 440. (29-33αA2-d) A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the nucleotide sequence shown in SEQ ID NO: 440. (29-33αA2-e) A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 440. (29-33αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 442 to 445, preferably a protein comprising at least two, three, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 442 to 445 may have one or more amino acids deleted, substituted, inserted, or added. (29-33αA3-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 447. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (29-33αA3-b)Sequence ID 447. (29-33αA3-c) A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 446. (29-33αA3-d) A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the nucleotide sequence shown in SEQ ID NO: 446. (29-33αA3-e) A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 446. (29-33αB3) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 448-451, preferably a protein comprising at least two, three, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 448-451 may have one or more amino acids deleted, substituted, inserted, or added.

[0228] Proteins selected from the group consisting of (29-33αA1-a)~(29-33αA1-e), (29-33αB1), (29-33αA2-a)~(29-33αA2-e), (29-33αB2), (29-33αA3-a)~(29-33αA3-e), and (29-33αB3) may appear as spots with a molecular weight of 10~70 kDa, preferably around 20~60 kDa, and an isoelectric point of 3.5~8.5, preferably 4.0~8.0, on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0229] Furthermore, the epitopes of the antigens (29-33αA1-a) to (29-33αA1-e) and (29-33αB1) are located at amino acids 66-75 (sequence number 838) and 301-315 (sequence number 839) of sequence number 435. If the antigen of spot 29-33α contains a mutation in the amino acid sequence of sequence number 435, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence in sequence number 435.

[0230] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy individuals are not judged as positive), the antigen of spot 29-33α may also be the following variants.

[0231] Of the epitopes having the sequence of SEQ ID NO: 838, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 836 or 837. Therefore, in another preferred embodiment, if the antigen of spot 29-33α contains a mutation in the amino acid sequence of SEQ ID NO: 435, then the antigen may have amino acids 66-75 in SEQ ID NO: 435 being the amino acid sequence of SEQ ID NO: 836 or 837.

[0232] Preferably, the antigen protein at spots 29α to 33α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 435 (glyceraldehyde-3-phosphate dehydrogenase isoform X1), the protein having the amino acid sequence of SEQ ID NO: 441 (glyceraldehyde-3-phosphate dehydrogenase, cytosolic), or the protein having the amino acid sequence of SEQ ID NO: 447 (uncharacterized protein LOC100782924), or is the cause of allergy to soy.

[0233] (34α) Spot 34α antigen Mass spectrometry analysis of spot 34α revealed the amino acid sequences corresponding to sequence numbers 454-458.

[0234] Furthermore, when the mass data obtained from the mass spectrometer for spot 34α was compared with NCBI's protein data and analyzed, bifunctional UDP-glucose 4-epimerase and UDP-xylose 4-epimerase 1-like (amino acid sequence: SEQ ID NO: 453, encoding nucleotide sequence: SEQ ID NO: 452) was identified as a protein containing SEQ ID NO: 454, and uncharacterized protein LOC100803483 (amino acid sequence: SEQ ID NO: 456, encoding nucleotide sequence: SEQ ID NO: 455) was identified as a protein containing either SEQ ID NO: 457 or 458.

[0235] Therefore, in this application, the antigen of spot 34α may be any protein selected from the group consisting of (34αA1-a) to (34αA1-e), (34αB1), (34αA2-a) to (34αA2-e), and (34αB2). (34αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 453. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (34αA1-b)Sequence ID 453. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (34αA1-c)Sequence ID 452. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (34αA1-d)Sequence ID 452, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (34αA1-e)SEQ ID NO: 452. (34αB1) A protein containing the amino acid sequence shown in SEQ ID NO: 454. Herein, the amino acid sequence shown in SEQ ID NO: 464 may have one or more amino acids deleted, substituted, inserted, or added. (34αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 456. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (34αA2-b)Sequence ID 456. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (34αA2-c)Sequence ID 455. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (34αA2-d)Sequence ID 455, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (34αA2-e)SEQ ID NO: 455. (34αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 457 and 458, preferably a protein comprising both of said amino acid sequences. Herein, the amino acid sequence represented by either SEQ ID NOs. 457 or 458 may have one or more amino acids deleted, substituted, inserted, or added.

[0236] Proteins selected from the group consisting of (34αA1-a) to (34αA1-e), (34αB1), (34αA2-a) to (34αA2-e), and (34αB2) may appear as spots with a molecular weight of 10 to 70 kDa, preferably around 20 to 60 kDa, and an isoelectric point of 5.5 to 10.5, preferably 6.0 to 10.0, in the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0237] Furthermore, the epitopes of the antigens (34αA1-a) to (34αA1-e) and (34αB1) are located at amino acids 61-75 (sequence number 842), 31-45 (sequence number 843), 141-155 (sequence number 844), 221-235 (sequence number 845), and 231-245 (sequence number 846) of sequence number 454. If the antigen of spot 34α contains a mutation in the amino acid sequence of sequence number 454, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence in sequence number 454.

[0238] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy individuals are not judged as positive), the spot34α antigen may also be one of the following variants.

[0239] Of the epitopes having the sequence of SEQ ID NO: 842, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 840 or 841. Therefore, in another preferred embodiment, if the antigen of spot 34α contains a mutation in the amino acid sequence of SEQ ID NO: 454, the antigen may have amino acids 61-75 in SEQ ID NO: 454 corresponding to the amino acid sequence of SEQ ID NO: 840 or 841. Preferably, the protein that is the antigen of spot 34α has activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 453 (bifunctional UDP-glucose 4-epimerase and UDP-xylose 4-epimerase 1-like) or a protein having the amino acid sequence of SEQ ID NO: 456 (uncharacterized protein LOC100803483), or is the cause of allergy to soy.

[0240] (35α) Spot 35α antigen Mass spectrometry analysis of spot 35α revealed the amino acid sequences corresponding to sequence numbers 461-477.

[0241] Furthermore, when the mass data obtained from the mass spectrometer for spot 35α was compared with NCBI's protein data and analyzed, the following proteins were identified: elongation factor 1-alpha (amino acid sequence: SEQ ID NO: 460, encoding nucleotide sequence: SEQ ID NO: 459) containing one of SEQ ID NOs: 461-466; elongation factor 1-alpha (amino acid sequence: SEQ ID NO: 468, encoding nucleotide sequence: SEQ ID NO: 467) containing one of SEQ ID NOs: 469-471; and elongation factor-1A isoform X1 (amino acid sequence: SEQ ID NO: 473, encoding nucleotide sequence: SEQ ID NO: 472) containing one of SEQ ID NOs: 474-477.

[0242] Therefore, in this application, the antigen of spot 35α may be any protein selected from the group consisting of (35αA1-a) to (35αA1-e), (35αB1), (35αA2-a) to (35αA2-e), (35αB2), (35αA3-a) to (35αA3-e), and (35αB3). (35αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 460. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (35αA1-b)Sequence ID 460. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (35αA1-c)Sequence ID 459. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (35αA1-d)Sequence ID 459, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (35αA1-e)Sequence ID 459. (35αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 461 to 466, preferably a protein comprising at least 2, 3, 4, 5, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 412 to 416 may have one or more amino acids deleted, substituted, inserted, or added. (35αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 468. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (35αA2-b)Sequence ID 468. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (35αA2-c)Sequence ID 467. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (35αA2-d)Sequence ID 467, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (35αA2-e)Sequence ID 467. (35αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 469 to 471, preferably a protein comprising at least two or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 469 to 471 may have one or more amino acids deleted, substituted, inserted, or added. (35αA3-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 473. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (35αA3-b)Sequence ID 473. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (35αA3-c)Sequence ID 472. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (35αA3-d)Sequence ID 472, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (35αA3-e)SEQ ID NO: 472. (35αB3) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 474 to 477, preferably a protein comprising at least two, three, or all of said amino acid sequences. Herein, the amino acid sequence represented by any of SEQ ID NOs: 474 to 477 may have one or more amino acids deleted, substituted, inserted, or added.

[0243] Proteins selected from the group consisting of (35αA1-a) to (35αA1-e), (35αB1), (35αA2-a) to (35αA2-e), (35αB2), (35αA3-a) to (35αA3-e), and (35αB3) may appear as spots with a molecular weight of 20 to 90 kDa, preferably around 30 to 80 kDa, and an isoelectric point of 5.5 to 10.5, preferably 6.0 to 10.0, on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0244] Furthermore, the epitopes of the antigens (35αA1-a) to (35αA1-e) and (35αB1) are located at amino acids 31-45 (sequence number 849), 121-135 (sequence number 850), 192-220 (sequence number 853), and 216-225 (sequence number 856) of sequence number 460. If the antigen of spot 35α contains a mutation in the amino acid sequence of sequence number 460, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence in sequence number 460.

[0245] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be identified as positive) and specificity (the degree to which healthy individuals are not identified as positive), the spot35α antigen may also be one of the following variants.

[0246] Of the epitopes having the sequence of SEQ ID NO: 849, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 847 or 848. Therefore, in another preferred embodiment, if the antigen of spot 35α contains a mutation in the amino acid sequence of SEQ ID NO: 460, then the antigen may have amino acids 31-45 in SEQ ID NO: 460 being the amino acid sequence of SEQ ID NO: 847 or 848.

[0247] Of the epitopes having the sequence of SEQ ID NO: 853, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 851 or 852. Therefore, in another preferred embodiment, if the antigen of spot 35α contains a mutation in the amino acid sequence of SEQ ID NO: 460, then the antigen may have amino acids 192-220 in SEQ ID NO: 460 being the amino acid sequence of SEQ ID NO: 851 or 852.

[0248] Of the epitopes having the sequence of SEQ ID NO: 856, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 854 or 855. Therefore, in another preferred embodiment, if the antigen of spot 35α contains a mutation in the amino acid sequence of SEQ ID NO: 460, then the antigen may have amino acids 216-225 in SEQ ID NO: 460 being the amino acid sequence of SEQ ID NO: 854 or 855.

[0249] Preferably, the antigen protein of spot 35α has activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 460 or 468 (elongation factor 1-alpha) or a protein having the amino acid sequence of SEQ ID NO: 473 (elongation factor-1A isoform X1), or is a cause of allergy to soy.

[0250] (36α, 37α) Spot 36α, 37α antigens Mass spectrometry analysis of spots 36α and 37α revealed the amino acid sequences corresponding to sequence numbers 480-493.

[0251] Furthermore, when the mass data obtained from the mass spectrometer for spots 36α and 37α were compared with NCBI's protein data and analyzed, the following proteins were identified: seed maturation protein PM34 (amino acid sequence: SEQ ID NO: 479, encoding nucleotide sequence: SEQ ID NO: 478) containing one of SEQ ID NOs: 480-483; uncharacterized protein LOC100809384 (amino acid sequence: SEQ ID NO: 485, encoding nucleotide sequence: SEQ ID NO: 484) containing one of SEQ ID NOs: 486 or 487; and hypothetical protein GLYMA_10G155300 (amino acid sequence: SEQ ID NO: 489, encoding nucleotide sequence: SEQ ID NO: 488) containing one of SEQ ID NOs: 4490-493.

[0252] Therefore, in this application, the antigens of spots 36α and 37α may be any protein selected from the group consisting of (36,37αA1-a)~(36,37αA1-e), (36,37αB1), (36,37αA2-a)~(36,37αA2-e), (36,37αB2), (36,37αA3-a)~(36,37αA3-e), and (36,37αB3). (36,37αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 479. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (36,37αA1-b)Sequence ID 479. A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (36,37αA1-c)Sequence ID 478. (36,37αA1-d) A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the nucleotide sequence shown in SEQ ID NO: 478. (36,37αA1-e) A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 478. (36,37αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 480-483, preferably a protein comprising at least two, three, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 480-483 may have one or more amino acids deleted, substituted, inserted, or added. (36,37αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 485. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (36,37αA2-b)Sequence ID 485. A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (36,37αA2-c)Sequence ID 484. (36,37αA2-d) A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the nucleotide sequence shown in SEQ ID NO: 484. (36,37αA2-e) A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 484. (36,37αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 486 and 487, preferably a protein comprising both of said amino acid sequences. Herein, the amino acid sequence represented by either SEQ ID NOs. 486 or 487 may have one or more amino acids deleted, substituted, inserted, or added. (36,37αA3-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 489. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (36,37αA3-b)Sequence ID 489. A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (36,37αA3-c)Sequence ID 488. (36,37αA3-d) A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the nucleotide sequence shown in SEQ ID NO: 488. (36,37αA3-e) A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 488. (36,37αB3) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 490-493, preferably a protein comprising at least two, three, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 490-493 may have one or more amino acids deleted, substituted, inserted, or added.

[0253] Proteins selected from the group consisting of (36,37αA1-a)~(36,37αA1-e), (36,37αB1), (36,37αA2-a)~(36,37αA2-e), (36,37αB2), (36,37αA3-a)~(36,37αA3-e), and (36,37αB3) may appear as spots with a molecular weight of 10~70 kDa, preferably around 20~60 kDa, and an isoelectric point of 3.5~8.5, preferably 4.0~8.0, on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0254] Furthermore, the epitopes of the antigens (36,37αA1-a) to (36,37αA1-e) and (36,37αB1) are located at amino acids 141-155 (sequence number 857), 231-245 (sequence number 858), and 7-14 (sequence number 861) of sequence number 479. If the antigens of spots 36α and 37α contain mutations in the amino acid sequence of sequence number 479, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence in sequence number 479.

[0255] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy individuals are not judged as positive), the antigens of spot 36α and 37α may be the following variants.

[0256] Of the epitopes having the sequence of SEQ ID NO: 861, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 859 or 860. Therefore, in another preferred embodiment, if the antigen of spot 36α,37α contains a mutation in the amino acid sequence of SEQ ID NO: 479, then the antigen may have amino acids 7-14 in SEQ ID NO: 479 being the amino acid sequence of SEQ ID NO: 859 or 860.

[0257] Preferably, the antigen proteins of spots 36α and 37α have activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 479 (seed maturation protein PM34), a protein having the amino acid sequence of SEQ ID NO: 485 (uncharacterized protein LOC100809384), or a protein having the amino acid sequence of SEQ ID NO: 489 (hypothetical protein GLYMA_10G155300), or are the cause of allergy to soy.

[0258] (38α) Spot 38α antigen Mass spectrometry analysis of spot 38α revealed the amino acid sequences corresponding to sequence numbers 496-513.

[0259] Furthermore, when the mass data obtained from the mass spectrometer for spot 38α was compared with NCBI's protein data and analyzed, seed biotin-containing protein SBP65-like isoform X1 (amino acid sequence: SEQ ID NO: 495, encoding nucleotide sequence: SEQ ID NO: 494) was identified as a protein containing one of SEQ ID NOs: 496-513.

[0260] Therefore, in this application, the antigen of spot 38α may be any protein selected from the group consisting of (38αA-a) to (38αA-e) and (38αB). (38αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 495. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (38αA-b)Sequence ID 495. (38αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 494. A protein comprising an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (38αA-d)Sequence ID 494, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (38αA-e)Sequence ID 494. (38αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 496-513, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs: 496-513 may have one or more amino acids deleted, substituted, inserted, or added.

[0261] The protein selected from the group consisting of (38αA-a) to (38αA-e) and (38αB) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 70 to 170 kDa, preferably around 80 to 160 kDa, and an isoelectric point of 5.5 to 10.5, preferably 6.0 to 10.0.

[0262] Furthermore, the epitopes of the spot 38α antigen are located at amino acids 440-446 or 574-580 (sequence number 864), amino acids 71-80 (sequence number 867), amino acids 521-535 (sequence number 869), amino acids 1-15 (sequence number 871), amino acids 31-45 (sequence number 874), amino acids 221-235 (sequence number 877), amino acids 461-470 (sequence number 882), amino acids 481-490 (sequence number 884), amino acids 821-835 (sequence number 887), amino acids 861-870 (sequence number 889), and amino acids 1031-1040 (sequence number 892) of sequence number 495. The spot 38α antigen may retain the sequence in sequence number 495 for amino acids at a position corresponding to at least one region of the epitope.

[0263] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy individuals are not judged as positive), the spot38α antigen may also be one of the following variants.

[0264] Of the epitopes having the sequence of SEQ ID NO: 864, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 862. Therefore, in another preferred embodiment, the antigen of spot 38α may be such that amino acids 440-446 and / or 574-580 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 862.

[0265] Of the epitopes having the sequence of SEQ ID NO: 867, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 865 or 866. Therefore, in another preferred embodiment, the antigen of spot 38α may be such that amino acids 71-80 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 865 or 866.

[0266] Of the epitopes having the sequence of SEQ ID NO: 869, the site important for binding to IgE antibodies in allergy patients is the site indicated by amino acids other than X in SEQ ID NO: 868. Therefore, in another preferred embodiment, the antigen of spot 38α may be such that amino acids 521-535 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 868.

[0267] Of the epitopes having the sequence of SEQ ID NO: 871, the site important for binding to IgE antibodies in allergy patients is the site indicated by amino acids other than X in SEQ ID NO: 870. Therefore, in another preferred embodiment, the antigen of spot 38α may be such that amino acids 1-15 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 870.

[0268] Of the epitopes having the sequence of SEQ ID NO: 874, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 872 or 873. Therefore, in another preferred embodiment, the antigen of spot 38α may be such that amino acids 31-45 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 872 or 873.

[0269] Of the epitopes having the sequence of SEQ ID NO: 877, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 875 or 876. Therefore, in another preferred embodiment, the antigen of spot 38α may be such that amino acids 221-235 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 875 or 876.

[0270] Of the epitopes having the sequence of SEQ ID NO: 880, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 878 or 879. Therefore, in another preferred embodiment, the antigen of spot 38α may be such that amino acids 311-325 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 878 or 879.

[0271] Of the epitopes having the sequence of SEQ ID NO: 882, the site important for binding to IgE antibodies in allergy patients is the site indicated by amino acids other than X in SEQ ID NO: 881. Therefore, in another preferred embodiment, the antigen of spot 38α may be such that amino acids 461-470 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 881.

[0272] Of the epitopes having the sequence of SEQ ID NO: 884, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 883. Therefore, in another preferred embodiment, the antigen of spot 38α may be such that amino acids 481-490 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 883.

[0273] Of the epitopes having the sequence of SEQ ID NO: 887, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 885 or 886. Therefore, in another preferred embodiment, the antigen of spot 38α may be such that amino acids 821-835 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 885 or 886.

[0274] Of the epitopes having the sequence of SEQ ID NO: 889, the site important for binding to IgE antibodies in allergy patients is the site indicated by amino acids other than X in SEQ ID NO: 888. Therefore, in another preferred embodiment, the antigen of spot 38α may be such that amino acids 861-870 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 888.

[0275] Of the epitopes having the sequence of SEQ ID NO: 892, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 890 or 891. Therefore, in another preferred embodiment, the antigen of spot 38α may be such that amino acids 1031-1040 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 890 or 891.

[0276] Preferably, the antigen protein of spot 38α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 495 (seed biotin-containing protein SBP65-like isoform X1), or is the cause of allergy to soy.

[0277] (39α) Spot 39α antigen Mass spectrometry analysis of spot 39α revealed the amino acid sequence of sequence number 516.

[0278] Furthermore, when the mass data obtained from the mass spectrometer for spot 39α was compared with NCBI's protein data and analyzed, the protein containing sequence number 516, ATP synthase subunit O, mitochondrial-like (amino acid sequence: sequence number 515, encoding nucleotide sequence: sequence number 514), was identified.

[0279] Therefore, in this application, the antigen of spot 39α may be any protein selected from the group consisting of (39αA-a) to (39αA-e) and (39αB). (39αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 515. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (39αA-b)Sequence ID 515. (39αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in SEQ ID NO: 514. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (39αA-d)Sequence ID 514, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (39αA-e)Sequence ID 514. (39αB) A protein containing the amino acid sequence shown in SEQ ID NO: 516. Herein, the amino acid sequence shown in SEQ ID NO: 516 may have one or more amino acids deleted, substituted, inserted, or added.

[0280] The protein selected from the group consisting of (39αA-a) to (39αA-e) and (39αB) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 5 to 60 kDa, preferably around 10 to 50 kDa, and an isoelectric point of 5.5 to 10.5, preferably 6.0 to 10.0.

[0281] Furthermore, the epitope of the spot 39α antigen is located at amino acids 71-85 (sequence number 895) of sequence number 515. The spot 39α antigen may retain the sequence of sequence number 515 for the amino acids at the position corresponding to the epitope region.

[0282] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be identified as positive) and specificity (the degree to which healthy individuals are not identified as positive), the spot39α antigen may also be one of the following variants.

[0283] Of the epitopes having the sequence of SEQ ID NO: 895, the site important for binding to IgE antibodies in allergy patients is the site represented by an amino acid other than X in SEQ ID NO: 893 or 894. Therefore, in another preferred embodiment, the antigen of spot 39α may be such that amino acids 71-85 in SEQ ID NO: 515 are the amino acid sequence of SEQ ID NO: 893 or 894.

[0284] Preferably, the antigen protein of spot 39α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 515 (ATP synthase subunit O, mitochondrial-like), or is the cause of allergy to soy.

[0285] (40α, 56α) Spot 40α, 56α antigens Mass spectrometry analysis of spots 40α and 56α revealed the amino acid sequences of sequence numbers 519 and 520.

[0286] Furthermore, when the mass data obtained from the mass spectrometer for spots 40α and 56α were compared with NCBI's protein data and analyzed, P24 oleosin isoform A (amino acid sequence: SEQ ID NO: 518, encoding nucleotide sequence: SEQ ID NO: 517) was identified as a protein containing either SEQ ID NO: 519 or 520.

[0287] Therefore, in this application, the antigens of spots 40α and 56α may be any protein selected from the group consisting of (40,56αA-a) to (40,56αA-e) and (40,56αB). (40,56αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 518. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (40,56αA-b)Sequence ID 518. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (40,56αA-c)Sequence ID 517. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (40,56αA-d)Sequence ID 517, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (40,56αA-e)SEQ ID NO: 517. (40,56αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 519 and 520, preferably a protein comprising both of said amino acid sequences. Herein, the amino acid sequence represented by either SEQ ID NOs. 519 or 520 may have one or more amino acids deleted, substituted, inserted, or added.

[0288] Proteins selected from the group consisting of (40,56αA-a) to (40,56αA-e) and (40,56αB) above may appear as spots with a molecular weight of 5 to 60 kDa, preferably around 10 to 50 kDa, and an isoelectric point of 5.5 to 10.5, preferably 6.0 to 10.0, in the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0289] Furthermore, the epitopes of the spot 40α and 56α antigens are located at amino acids 35-39 (sequence number 898), 191-205 (sequence number 899), and 214-222 (sequence number 902) of sequence number 518. The spot 40α and 56α antigens may retain the sequence of sequence number 518 for the amino acids at the positions corresponding to the epitope region.

[0290] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy individuals are not judged as positive), the spot 40α and 56α antigens may also be the following variants.

[0291] Of the epitopes having the sequence of SEQ ID NO: 898, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 896 or 897. Therefore, in another preferred embodiment, the antigen of spot 40α,56α may be such that amino acids 35-39 in SEQ ID NO: 518 are the amino acid sequence of SEQ ID NO: 896 or 897.

[0292] Of the epitopes having the sequence of SEQ ID NO: 902, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 900 or 901. Therefore, in another preferred embodiment, the antigen of spot 40α,56α may be such that amino acids 214-2229 in SEQ ID NO: 518 are the amino acid sequence of SEQ ID NO: 900 or 901.

[0293] Preferably, the antigen proteins of spots 40α and 56α have activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 518 (P24 oleosin isoform A), or they cause allergies to soy.

[0294] (41α) Spot 41α antigen Mass spectrometry analysis of spot 41α revealed the amino acid sequence of sequence number 523.

[0295] Furthermore, when the mass data obtained from the mass spectrometer for spot 41α was compared with NCBI's protein data and analyzed, the protein containing sequence number 523, uncharacterized protein At3g49720-like isoform X2 (amino acid sequence: sequence number 522, nucleotide sequence encoding it: sequence number 521), was identified.

[0296] Therefore, in this application, the antigen of spot 41α may be any protein selected from the group consisting of (41αA-a) to (41αA-e) and (41αB). (41αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 522. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (41αA-b)Sequence ID 522. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (41αA-c)Sequence ID 521. A protein comprising an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (41αA-d)Sequence ID 521, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (41αA-e)Sequence ID 521. (41αB) A protein containing the amino acid sequence shown in Sequence ID No. 523. Herein, the amino acid sequence shown in Sequence ID No. 523 may have one or more amino acids deleted, substituted, inserted, or added.

[0297] The protein selected from the group consisting of (41αA-a) to (41αA-e) and (41αB) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 5 to 60 kDa, preferably around 10 to 50 kDa, and an isoelectric point of 5.5 to 10.5, preferably 6.0 to 10.0.

[0298] Furthermore, the epitope of the spot 41α antigen is located at amino acids 111-125 of sequence number 522 (sequence number 903). The spot 41α antigen may retain the sequence of sequence number 522 for the amino acids at the position corresponding to the epitope region.

[0299] Preferably, the antigen protein of spot 41α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 515 (ATP synthase subunit O, mitochondrial-like), or is the cause of allergy to soy.

[0300] (42α, 43α) Spot 42α, 43α antigens Mass spectrometry analysis of spots 42α and 43α revealed the amino acid sequences corresponding to sequence numbers 526-539.

[0301] Furthermore, when the mass data obtained from the mass spectrometer for spots 42α and 43α were compared with NCBI's protein data and analyzed, superoxide dismutase [Mn], mitochondrial (amino acid sequence: SEQ ID NO: 525, encoding nucleotide sequence: SEQ ID NO: 524) was identified as a protein containing one of SEQ ID NOs. 526-531, and hypothetical protein GLYMA_04G221300 (amino acid sequence: SEQ ID NO: 533, encoding nucleotide sequence: SEQ ID NO: 532) was identified as a protein containing one of SEQ ID NOs. 534-539.

[0302] Therefore, in this application, the antigens of spots 42α and 43α may be any protein selected from the group consisting of (42,43αA1-a) to (42,43αA1-e), (42,43αB1), (42,43αA2-a) to (42,43αA2-e), and (42,43αB2). (42,43αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 525. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (42,43αA1-b)Sequence ID 525. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (42,43αA1-c)Sequence ID 524. (42,43αA1-d) A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the nucleotide sequence shown in SEQ ID NO: 524. (42,43αA1-e) A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 524. (42,43αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 526-531, preferably a protein comprising at least 2, 3, 4, 5, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 526-531 may have one or more amino acids deleted, substituted, inserted, or added. (42,43αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 533. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (42,43αA2-b)Sequence ID 533. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (42,43αA2-c)Sequence ID 532. (42,43αA2-d) A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the nucleotide sequence shown in SEQ ID NO: 532. (42,43αA2-e) A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 532. (42,43αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 534-539, preferably a protein comprising at least 2, 3, 4, 5, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 534-539 may have one or more amino acids deleted, substituted, inserted, or added.

[0303] Proteins selected from the group consisting of (42,43αA1-a) to (42,43αA1-e), (42,43αB1), (42,43αA2-a) to (42,43αA2-e), and (42,43αB2) may appear as spots with a molecular weight of 5 to 60 kDa, preferably around 10 to 50 kDa, and an isoelectric point of 5.5 to 10.5, preferably 6.0 to 10.0, on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0304] Furthermore, the epitopes of the antigens (42,43αA1-a) to (42,43αA1-e) and (42,43αB1) are located at amino acids 227 to 241 (sequence number 906) of sequence number 525. If the antigens of spots 42α and 43α contain mutations in the amino acid sequence of sequence number 525, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence of sequence number 525.

[0305] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy individuals are not judged as positive), the antigens of spot 42α and 43α may be the following variants.

[0306] Of the epitopes having the sequence of SEQ ID NO: 906, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 904 or 905. Therefore, in another preferred embodiment, if the antigen of spot 42α,43α contains a mutation in the amino acid sequence of SEQ ID NO: 525, then the antigen may have amino acids 227-241 in SEQ ID NO: 525 being the amino acid sequence of SEQ ID NO: 904 or 905.

[0307] Preferably, the antigen proteins of spots 42α and 43α have activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 525 (superoxide dismutase [Mn], mitochondrial) or the protein having the amino acid sequence of SEQ ID NO: 533 (hypothetical protein GLYMA_04G221300), or are the cause of allergy to soy.

[0308] (45α) Spot 45α antigen Mass spectrometry analysis of spot 45α revealed the amino acid sequence corresponding to sequence numbers 542-551.

[0309] Furthermore, when the mass data obtained from the mass spectrometer for spot 45α was compared with NCBI's protein data and analyzed, the uncharacterized protein LOC100499771 (amino acid sequence: SEQ ID NO: 541, encoding nucleotide sequence: SEQ ID NO: 540) was identified as a protein containing one of SEQ ID NOs. 542-545, and the hypothetical protein GLYMA_09G192800 (amino acid sequence: SEQ ID NO: 547, encoding nucleotide sequence: SEQ ID NO: 546) was identified as a protein containing one of SEQ ID NOs. 548-551.

[0310] Therefore, in this application, the antigen of spot 45α may be any protein selected from the group consisting of (45αA1-a) to (45αA1-e), (45αB1), (45αA2-a) to (45αA2-e), and (45αB2). (45αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 541. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (45αA1-b)Sequence ID 541. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (45αA1-c)Sequence ID 540. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (45αA1-d)SEQ ID NO: 540, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (45αA1-e)SEQ ID NO: 540. (45αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 542 to 545, preferably a protein comprising at least two, three, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 542 to 545 may have one or more amino acids deleted, substituted, inserted, or added. (45αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 547. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (45αA2-b)Sequence ID 547. A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (45αA2-c)Sequence ID 546. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (45αA2-d)Sequence ID 546, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (45αA2-e)SEQ ID NO: 546. (45αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 548 to 551, preferably a protein comprising at least two, three, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 548 to 551 may have one or more amino acids deleted, substituted, inserted, or added.

[0311] Proteins selected from the group consisting of (45αA1-a) to (45αA1-e), (45αB1), (45αA2-a) to (45αA2-e), and (45αB2) may appear as spots with a molecular weight of 2 to 50 kDa, preferably around 5 to 40 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, on a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0312] Furthermore, the epitopes of the antigens (45αA1-a) to (45αA1-e) and (45αB1) are located at amino acids 11-25 (sequence number 910), 51-65 (sequence number 911), and 111-125 (sequence number 912) of sequence number 541. If the spot 45α antigen contains mutations in the amino acid sequence of sequence number 541, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence of sequence number 541.

[0313] Preferably, the antigen protein of spot 45α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 541 (uncharacterized protein LOC100499771) or the protein having the amino acid sequence of SEQ ID NO: 547 (hypothetical protein GLYMA_09G192800), or is the cause of allergy to soy.

[0314] (46α) Spot 46α antigen Mass spectrometry analysis of spot 46α revealed the presence of the amino acid sequence corresponding to sequence number 554.

[0315] Furthermore, when the mass data obtained from the mass spectrometer for spot 46α was compared with NCBI's protein data and analyzed, seed maturation protein PM22 (amino acid sequence: sequence number 553, encoding nucleotide sequence: sequence number 552) was identified as a protein containing sequence number 554.

[0316] Therefore, in this application, the antigen of spot 46α may be any protein selected from the group consisting of (46αA-a) to (46αA-e) and (46αB). (46αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 553. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (46αA-b)Sequence ID 553. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (46αA-c)Sequence ID 552. A protein comprising an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (46αA-d)Sequence ID 552, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (46αA-e)Sequence ID 552. (46αB) A protein containing the amino acid sequence shown in SEQ ID NO: 554. Herein, the amino acid sequence shown in SEQ ID NO: 554 may have one or more amino acids deleted, substituted, inserted, or added.

[0317] The protein selected from the group consisting of (46αA-a) to (46αA-e) and (46αB) above may be a protein that appears as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 2 to 50 kDa, preferably around 5 to 40 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0.

[0318] Furthermore, the epitope of the spot 46α antigen is located at amino acids 112-120 (sequence number 915) of sequence number 553. The spot 46α antigen may retain the sequence of sequence number 553 for the amino acids at the position corresponding to the epitope region.

[0319] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy individuals are not judged as positive), the spot 46α antigen may also be one of the following variants.

[0320] Of the epitopes having the sequence of SEQ ID NO: 915, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 913 or 914. Therefore, in another preferred embodiment, the antigen of spot 46α may be such that amino acids 112-120 in SEQ ID NO: 553 are the amino acid sequence of SEQ ID NO: 913 or 914.

[0321] Preferably, the antigen protein of spot 46α has activity equivalent to that of the protein having the amino acid sequence of sequence number 553 (seed maturation protein PM22), or is the cause of allergy to soy.

[0322] (47α) Spot 47α antigen Mass spectrometry analysis of spot 47α revealed the amino acid sequences corresponding to sequence numbers 557-563.

[0323] Furthermore, when the mass data obtained from the mass spectrometer for spot 47α was compared with NCBI's protein data and analyzed, eukaryotic translation initiation factor 5A-2 (amino acid sequence: SEQ ID NO: 556, encoding nucleotide sequence: SEQ ID NO: 555) was identified as a protein containing either SEQ ID NOs. 557 or 558, and uncharacterized protein LOC100305510 (amino acid sequence: SEQ ID NO: 560, encoding nucleotide sequence: SEQ ID NO: 559) was identified as a protein containing either SEQ ID NOs. 561 to 563.

[0324] Therefore, in this application, the antigen of spot 47α may be any protein selected from the group consisting of (47αA1-a) to (47αA1-e), (47αB1), (47αA2-a) to (47αA2-e), and (47αB2). (47αA1-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 556. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown by (47αA1-b)Sequence ID 556. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (47αA1-c)Sequence ID 555. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (47αA1-d)SEQ ID NO: 555, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (47αA1-e)SEQ ID NO: 555. (47αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 557 and 558, preferably a protein comprising both of said amino acid sequences. Herein, the amino acid sequence represented by either SEQ ID NOs. 557 or 558 may have one or more amino acids deleted, substituted, inserted, or added. (47αA2-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 560. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (47αA2-b)Sequence ID 560. A protein containing an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (47αA2-c)Sequence ID 559. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (47αA2-d)Sequence ID 559, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (47αA2-e)SEQ ID NO: 559. (47αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 561 to 563, preferably a protein comprising at least two or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 548 to 551 may have one or more amino acids deleted, substituted, inserted, or added.

[0325] Proteins selected from the group consisting of (47αA1-a) to (47αA1-e), (47αB1), (47αA2-a) to (47αA2-e), and (47αB2) may appear as spots with a molecular weight of 2 to 50 kDa, preferably around 5 to 40 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, on a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0326] Furthermore, the epitopes of the antigens (47αA1-a) to (47αA1-e) and (47αB1) are located at amino acids 11-25 (sequence number 916), 81-95 (sequence number 917), and 131-145 (sequence number 918) of sequence number 556. If the antigen of spot 47α contains a mutation in the amino acid sequence of sequence number 556, the amino acids at the position corresponding to at least one region of the epitope may retain the sequence of sequence number 556.

[0327] Preferably, the antigen protein of spot 47α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 556 (eukaryotic translation initiation factor 5A-2) or the protein having the amino acid sequence of SEQ ID NO: 560 (uncharacterized protein LOC100305510), or is the cause of allergy to soy.

[0328] (48α) Spot 48α antigen Mass spectrometry analysis of spot 48α revealed the amino acid sequence corresponding to sequence numbers 566-570.

[0329] Furthermore, when the mass data obtained from the mass spectrometer for spot 48α was compared with NCBI's protein data and analyzed, the uncharacterized protein LOC100306570 (amino acid sequence: SEQ ID NO: 565, encoding nucleotide sequence: SEQ ID NO: 564) was identified as a protein containing one of SEQ ID NOs: 566 to 570.

[0330] Therefore, in this application, the antigen of spot 48α may be any protein selected from the group consisting of (48αA-a) to (48αA-e) and (48αB). (48αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 565. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (48αA-b)Sequence ID 565. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (48αA-c)Sequence ID 564. A protein comprising an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (48αA-d)Sequence ID 564, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (48αA-e)Sequence ID 564. (48αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 566 to 570, preferably a protein comprising at least two, three, four, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 566 to 570 may have one or more amino acids deleted, substituted, inserted, or added.

[0331] The protein selected from the group consisting of (48αA-a) to (48αA-e) and (48αB) above may appear as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 2 to 50 kDa, preferably around 5 to 40 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0.

[0332] Furthermore, the epitope of the spot 48α antigen is located at amino acids 94-102 (sequence number 921) and 131-145 (sequence number 922) of sequence number 565. The spot 48α antigen may retain the sequence of sequence number 565 for the amino acids at the positions corresponding to the epitope region.

[0333] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy individuals are not judged as positive), the spot 48α antigen may also be one of the following variants.

[0334] Of the epitopes having the sequence of SEQ ID NO: 921, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other than X in SEQ ID NO: 919 or 918. Therefore, in another preferred embodiment, the antigen of spot 48α may be such that amino acids 94-102 in SEQ ID NO: 565 are the amino acid sequence of SEQ ID NO: 919 or 918.

[0335] Preferably, the antigen protein of spot 48α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 565 (uncharacterized protein LOC100306570), or is the cause of allergy to soy.

[0336] (50α) Spot 50α antigen Mass spectrometry analysis of spot 50α revealed the amino acid sequences corresponding to sequence numbers 573-576.

[0337] Furthermore, when the mass data obtained from the mass spectrometer for spot 50α was compared with NCBI's protein data and analyzed, uncharacterized protein LOC100813859 (amino acid sequence: SEQ ID NO: 572, encoding nucleotide sequence: SEQ ID NO: 571) was identified as a protein containing one of SEQ ID NOs: 573 to 576.

[0338] Therefore, in this application, the antigen of spot 50α may be any protein selected from the group consisting of (50αA-a) to (50αA-e) and (50αB). (50αA-a) A protein containing an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in sequence number 572. A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in (50αA-b)Sequence ID 572. A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides are deleted, substituted, inserted, or added in (50αA-c)Sequence ID 571. A protein containing an amino acid sequence encoded by a nucleotide sequence that is 70% or more identical to the nucleotide sequence shown in (50αA-d)Sequence ID 571, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more. A protein containing an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in (50αA-e)Sequence ID 571. (50αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 573 to 576, preferably a protein comprising at least two, three, or all of the sequences of said amino acid sequence. Herein, the amino acid sequence represented by any of SEQ ID NOs. 573 to 576 may have one or more amino acids deleted, substituted, inserted, or added.

[0339] The protein selected from the group consisting of (50αA-a) to (50αA-e) and (50αB) above may be a protein that appears as a spot on the gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above, with a molecular weight of 2 to 50 kDa, preferably around 5 to 40 kDa, and an isoelectric point of 2.5 to 6.5, preferably 3.0 to 6.0.

[0340] Furthermore, the epitope of the spot 50α antigen is located at amino acids 91-105 (sequence number 924) and 62-70 (sequence number 927) of sequence number 572. The spot 50α antigen may retain the sequence of sequence number 572 for the amino acids at the positions corresponding to the epitope region.

[0341] Furthermore, from the perspective of improving sensitivity (the degree to which patients can be identified as positive) and specificity (the degree to which healthy individuals are not identified as positive), the antigen of Spot 50α may also be one of the following variants.

[0342] Of the epitopes having the sequence of SEQ ID NO: 927, the site important for binding to IgE antibodies in allergy patients is the site indicated by an amino acid other th...

Claims

1. A polypeptide that specifically binds to IgE antibodies in allergy patients, and the following: (1β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 650-660; (2β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 661-692; (4β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 717-731; (5β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 732-738; (6β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 739 and 740; (7β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 741-744; (9β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 745-749; (11β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 751-754; (12β) Polypeptide containing the amino acid sequence of SEQ ID NO: 755; (13β) Polypeptides containing the amino acid sequences of SEQ ID NOs. 756-758; (14β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 759-764; (15β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 765 and 766; (17β) Polypeptide containing the amino acid sequence of SEQ ID NO: 767; (18β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 750, 768-775; (19β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 776-787; (25β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 814 and 815; (26β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 816-819; (27β) Polypeptide containing the amino acid sequence of SEQ ID NO: 820; (28β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 821-835; (29β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 836-839; (34β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 840-846; (35β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 847-856; (36β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 857-861; (38β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 862-892; (39β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 893-895; (40β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 896-902; (41β) Polypeptide containing the amino acid sequence of SEQ ID NO: 903; (42β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 904-906; (45β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 910-912; (46β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 913-915; (47β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 916-918; (48β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 919-922; (50β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 924-927; (51β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 928-930; (52β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 931-938; (53β) Polypeptide containing the amino acid sequence of SEQ ID NO: 939; (54β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 940-943; (55β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 944-952; The polypeptide, which is one of the following.

2. A polypeptide that specifically binds to IgE antibodies in allergy patients, and the following: (3β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 693-716; (20β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 788-792; (21β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 793-802; (22β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 803-808; (23β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 809-812; (24β) Polypeptide containing the amino acid sequence of SEQ ID NO: 813; (44β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 907-909; (49β) Polypeptide containing the amino acid sequence of SEQ ID NO: 923; (57β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 953-955; (58β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs. 956-960; (59β) Polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 961 and 962; (60β) Polypeptide containing the amino acid sequence of SEQ ID NO: 963; The polypeptide, which is one of the following.

3. A polypeptide according to either claim 1 or 2, wherein the number of amino acid residues is 500 or less.

4. An allergy diagnostic kit comprising at least one polypeptide according to any one of claims 1 to 3.

5. A diagnostic composition for allergies, comprising at least one polypeptide according to any one of claims 1 to 3 as an antigen.

6. A method for providing indicators for diagnosing a target allergy, comprising the following steps: (i) The sample obtained from the subject is brought into contact with the antigen, where the sample is a solution containing Ig antibody; (ii) Detect the binding of IgE antibodies to the antigen in the sample obtained from the subject; (iii) If binding of the target IgE antibody to the antigen is detected, it provides an indicator that the subject is an allergen; The method comprising, wherein the antigen is at least one polypeptide according to any one of claims 1 to 3.

7. A pharmaceutical composition comprising at least one polypeptide according to any one of claims 1 to 3.

8. A pharmaceutical composition according to claim 7 for treating allergies.

9. A tester for determining the presence or absence of an antigen in a target object, characterized by comprising an antibody that binds to at least one polypeptide according to any one of claims 1 to 3.

10. A food ingredient or processed food product characterized in that an antigen is removed or reduced, or a polypeptide is cleaved or removed, wherein the antigen is at least one of the polypeptides described in any one of claims 1 to 3.

11. A method for producing an edible processed product in which an antigen has been removed or reduced, or a polypeptide has been cleaved or removed, the method comprising a step of confirming that the antigen has been removed or reduced, or that the polypeptide has been cleaved or removed, during the production process of the processed product, wherein the antigen is at least one of the polypeptides described in any one of claims 1 to 3.

Images